Long Stokes shift chromophore quinoline dyes and their use in sequencing applications

CN115916908BActive Publication Date: 2024-11-19ILLUMINA CAMBRIDGE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180046792.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-12-17
Filing Date
2021-12-16
Publication Date
2024-11-19
Estimated Expiration
2041-12-16

Smart Images

  • Figure CN115916908B_ABST
    Figure CN115916908B_ABST
Patent Text Reader

Abstract

The present application relates to long Stokes shift chromene and quinoline dyes and their use as fluorescent markers. For example, these dyes can be used to label nucleotides for nucleic acid sequencing applications. These chromene and quinoline dyes have formula (I). #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to chromenoquinoline dyes and their use as fluorescent markers. Specifically, these compounds can be used as nucleotide markers for nucleic acid sequencing applications. Background Art

[0002] Nonradioactive detection of fluorescently labeled nucleic acids is an important technique in molecular biology. Many procedures employed in recombinant DNA technology have previously relied on the use of radioactively labeled nucleotides or polynucleotides, e.g. 32 P. Radioactive compounds allow sensitive detection of nucleic acids and other molecules of interest. However, there are serious limitations in the use of radioisotopes, such as their expense, limited shelf life, insufficient sensitivity, and more importantly, safety considerations. Eliminating the need for radiolabeling reduces both safety risks and environmental impacts and costs associated with, for example, reagent handling. Methods suitable for non-radioactive fluorescence detection include, by way of non-limiting example, automated DNA sequencing, hybridization methods, real-time detection of polymerase chain reaction products, and immunoassays.

[0003] For many applications, it is desirable to employ multiple spectrally distinguishable fluorescent labels in order to achieve independent detection of multiple spatially overlapping analytes. In such multiplex methods, the number of reaction vessels can be reduced, thereby simplifying the experimental protocol and facilitating the production of specialized kits. For example, in multicolor automated DNA sequencing systems, multiplex fluorescence detection allows the analysis of multiple nucleotide bases in a single electrophoretic channel, thereby increasing throughput over a monochromatic approach and reducing the uncertainty associated with inter-channel electrophoretic mobility variations.

[0004] However, multiple fluorescence detection may be problematic, and many important factors present can limit the selection of appropriate fluorescent labels. First, it may be difficult to find dye compounds with substantially resolved absorption and emission spectra in a given application. In addition, when several fluorescent dyes are used together, it may be complicated to produce fluorescent signals in distinguishable spectral regions by simultaneous excitation, because the absorption bands of these dyes are usually very separate, so even two dyes are also difficult to achieve comparable fluorescence excitation efficiency. Many excitation methods use high-power light sources, such as lasers, so dyes must have enough photostability to withstand such excitations. The last consideration that is particularly important to molecular biology methods is the degree to which fluorescent dyes must be compatible with reagent chemistry (such as DNA synthesis solvents and reagents, buffers, polymerases and ligases).

[0005] As sequencing technology progresses, there is a need to develop additional fluorescent dye compounds, nucleic acid conjugates thereof, and multiple dye sets that meet all of the above limitations and are particularly suitable for high-throughput molecular methods (such as solid-phase sequencing, etc.).

[0006] Fluorescent dye molecules with improved fluorescence properties (such as the wavelength maximum of suitable fluorescence intensity, shape and fluorescence band) can improve the speed and accuracy of nucleic acid sequencing. When measured in water-based biological buffer and at higher temperatures, strong fluorescent signals are particularly important because the fluorescence intensity of most organic dyes is significantly lower under such conditions. In addition, the property of the base to which the dye is attached also affects other spectral characteristics of fluorescence maximum, fluorescence intensity and dye. The sequence-specific interaction between core base and fluorescent dye can be customized by the specific design of fluorescent dye. The optimization of fluorescent dye structure can improve the efficiency of nucleotide incorporation, reduce the level of sequencing errors, and reduce the use of reagents in nucleic acid sequencing, thereby reducing the cost of nucleic acid sequencing.

[0007] Some optical and technological developments have led to great improvements in image quality, but are ultimately limited by poor optical resolution. In general, the optical resolution of optical microscopy is limited to objects spaced at approximately half the wavelength of the light used. In practice, only objects that are quite far apart (at least 200nm to 350nm) can be resolved by optical microscopy. One way to improve image resolution and increase the number of resolvable objects per unit surface area is to use excitation light of a shorter wavelength. For example, if the wavelength of light is shortened by Δλ by about 100nm with the same optics, the resolution will be better (about Δ50nm / (about 15%)), less distorted images will be recorded, and the density of objects on the identifiable area will increase by about 35%.

[0008] Some nucleic acid sequencing methods use lasers to excite dye-labeled nucleotides and detect them. These instruments use longer wavelength light, such as red lasers, together with appropriate dyes that can be excited at 660nm. In order to detect more densely packed nucleic acid sequencing clusters while maintaining available resolution, a shorter wavelength blue light source (450nm to 460nm) can be used. In this case, the optical resolution will not be limited by the emission wavelength of the longer wavelength red fluorescent dye, but by the emission of the dye that can be excited by the secondary long wavelength light source (for example, by the "green laser" at 532nm). Therefore, it is necessary to use blue dye labels for fluorescence detection in sequencing applications.

[0009] Chromen and quinoline dyes have been reported in the literature as fluorescent probes or mitochondrial markers. See Geng et al., Sensors & Actuators: B. Chemical, 2018, Vol. 273: pp. 1670-1675, and Liu et al., Chemical Communications, 2018, Vol. 54, No. 12: pp. 1509-1512. However, most of these chromen and quinoline dyes have red emission and their stability under aqueous conditions for nucleotide sequencing is still unknown. Therefore, designing chromen and quinoline dyes with customized adsorption wavelength and fluorescence Stokes shift, with good stability, remains a key challenge in dye development. Summary of the invention

[0010] The chrome ene and quinoline dyes with long Stokes shift and improved fluorescence intensity and chemical stability that are suitable for nucleotide labeling and order-checking application are described herein.These chrome ene and quinoline dyes all have hyperfluorescence (for example, these chrome ene and quinoline dyes can have an absorption wavelength of about 450nm to about 530nm, about 460nm to about 520nm, about 475nm to about 510nm or about 490nm to about 500nm) under blue light and green light excitation.In addition, compared with the commercially available dye for synthetic order-checking, these chrome ene and quinoline dyes have higher stability in high pH buffer.

[0011] Some aspects of the present disclosure relate to compounds of formula (I) or salts or meso forms thereof:

[0012]

[0013] Where R 1 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12a and R 12b each of which is independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, (C1-C6 alkoxy)C1-C6 alkyl, optionally substituted amino, amino(C1-C6 alkyl), halo, cyano, hydroxy, hydroxy(C1-C6 alkyl), nitro, sulfonyl, sulfo, sulfinyl, sulfonate, S-sulfonamido, or N-sulfonamido;

[0014] R 2 and R 3Each of is independently H, C1-C6 alkyl or substituted C1-C6 alkyl; and

[0015] R 6 is C1-C6 alkyl or substituted C1-C6 alkyl;

[0016] Alternatively, R 1 and R 2 together with the atoms to which they are attached form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 5- to 10-membered heterocyclyl; and / or

[0017] Alternatively, R 3 and R 4 together with the atoms to which they are attached form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 5- to 10-membered heterocyclyl; and / or

[0018] Alternatively, R 8 and R 9 Together with the atoms to which they are attached, they form an optionally substituted C6-C 10 In some embodiments, when R 2 and R 3 Each of R is ethyl; 1 , R 4 , R 5 , R 7 , R 8 , R 10 , R 11 , R 12a and R 12b Each of is H; and R 6 When it is methyl, then R 9 is a substituted C1-C6 alkyl group containing a carboxyl group. 1 and R 2 Together with the atoms to which they are attached, they form a piperidinyl group, and R 3 and R 4 Together with the atoms to which they are attached, they form a piperidinyl group, giving the compound the structure R 5 , R 7 , R 8 , R 10 , R 11 , R 12a and R 12b Each of is H; and R 6 When it is methyl, then R 9It is a substituted C1-C6 alkyl group containing a carboxyl group.

[0019] In some embodiments, the compound of formula (I) is also represented by formula (Ia) or a salt or meso form thereof:

[0020]

[0021] Where R 13a , R 13b , R 14a and R 14b Each of the above is independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, (C1-C6 alkoxy)C1-C6 alkyl, optionally substituted amino, amino(C1-C6 alkyl), halo, cyano, hydroxy, hydroxy(C1-C6 alkyl), nitro, sulfonyl, sulfo, sulfinyl, sulfonate, S-sulfonamido or N-sulfonamido; and the solid and dashed lines represent the following: The bond represented by is selected from the group consisting of single bonds and double bonds, provided that when When it is a double bond, R 14b Does not exist.

[0022] In some embodiments of the compound of Formula (I) or Formula (Ia), R 6 , R 7 , R 8 , R 9 , R 10 and R 11 In other embodiments, R 2 or R 3 Contains a carboxyl group.

[0023] In some aspects, the compounds of the present disclosure are labeled with or conjugated to substrate moieties such as nucleosides, nucleotides, polynucleotides, polypeptides, carbohydrates, ligands, particles, cells, semisolid surfaces (e.g., gels), or solid surfaces. Labeling or conjugation can be via a carboxyl group, which can react with an amino or hydroxyl group on a moiety such as a nucleotide or a linker bound thereto to form an amide or ester using methods known in the art.

[0024] Some other aspects of the present disclosure relate to dye compounds comprising a linker group to achieve, for example, covalent attachment to a substrate moiety. Connection can be made at any position of the dye, including at any of the R groups. In some embodiments, the connection can be made via R 6 , R 7 , R 8 , R9 , R 10 and R 11 or through R of formula (I) 2 or R 3 In some further embodiments, the connection can be via R 6 , R 7 , R 8 , R 9 , R 10 and R 11 or through R of formula (Ia) 2 conduct.

[0025] Some other aspects of the present disclosure provide labeled nucleoside or nucleotide compounds defined by the following formula:

[0026] NL-Dye

[0027] wherein N is a nucleoside or a nucleotide;

[0028] L is an optional linker moiety; and

[0029] The dye is part of a fluorescent compound of formula (I) or formula (Ia) according to the present disclosure, wherein a functional group (e.g., a carboxyl group) of the compound of formula (I) or formula (Ia) reacts with a linker moiety or an amino or hydroxyl group of a nucleoside / nucleotide to form a covalent bond.

[0030] Some additional aspects of the disclosure relate to nucleotides or oligonucleotides labeled with compounds of Formula (I) or Formula (Ia).

[0031] Some other aspects of the present disclosure relate to a test kit comprising dye compounds (free or labeled form) that can be used for various immunological assays, oligonucleotides or nucleic acid markers or for DNA synthesis sequencing. In yet another aspect, the present disclosure provides a test kit comprising a dye "set" that is particularly suitable for synthesis sequencing cycles on an automated instrument platform. In some aspects, a test kit comprising one or more nucleotides, wherein at least one nucleotide is a labeled nucleotide as described herein.

[0032] Another aspect of the present disclosure is a method of determining the sequence of a target polynucleotide, the method comprising:

[0033] (a) contacting the primer polynucleotide / target polynucleotide complex with one or more labeled nucleotides (e.g., A, G, C, and T or dATP, dGTP, dCTP, and dTTP), wherein at least one of the labeled nucleotides is a nucleotide labeled with a chromenoquinoline dye of Formula (I) or Formula (Ia) as described herein, and wherein the primer polynucleotide is complementary to at least a portion of the target polynucleotide;

[0034] (b) incorporating a labeled nucleotide into the primer polynucleotide to generate an extended primer polynucleotide / target polynucleotide complex; and

[0035] (c) performing one or more fluorescence measurements on the extended primer polynucleotide / target polynucleotide complex to determine the identity of the incorporated nucleotide. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Shown are the absorption spectra of ffA nucleotides conjugated to chromenoquinoline dyes 1-1 to 1-6 and 1-8 as 2 μM solutions in Universal Scan Mix (USM).

[0037] FIG. 2A to FIG. 2B Shown are the fluorescence emission spectra of ffA nucleotides conjugated with chromenoquinoline dyes 1-1, 1-2, 1-5 and 1-6 obtained in USM using 520 nm or 450 nm as the excitation wavelength, respectively.

[0038] Figure 2C to Figure 2D Shown are the fluorescence emission spectra of ffA nucleotides conjugated with chromenoquinoline dyes 1-3, 1-4 and 1-8 obtained in USM using 520 nm or 450 nm as the excitation wavelength, respectively.

[0039] Figure 3A Shown are the percent remaining fluorescence of two ffAs conjugated to chromenoquinoline dyes 1-3 and 1-4 in ethanolamine buffer at 45°C, compared to that of ffC conjugated to coumarin reference dye A under the same conditions.

[0040] Figure 3B Shown are the remaining percent fluorescence of two ffAs conjugated with chromenoquinoline dyes 1-3 and 1-4 under the same conditions compared to ffC conjugated with coumarin reference dye A in glycine buffer at 45°C.

[0041] Figure 3C Shown are the remaining percent fluorescence of two ffAs conjugated with chromenoquinoline dyes 1-3 and 1-4 under the same conditions compared to ffC conjugated with coumarin reference dye A in TRIS buffer at 40°C.

[0042] Figure 3D Shown are the remaining percent fluorescence of two ffAs conjugated with chromenoquinoline dyes 1-3 and 1-4 under the same conditions compared to ffC conjugated with coumarin reference dye A in MOPS buffer at 40 °C.

[0043] FIG. 4A to FIG. 4E Shown in the Illumina iSeqTM Scatter plot obtained on an IAQ 100 instrument using a spike-in mixture having ffA nucleotides labeled with chromanoquinoline dyes 1-1, 1-2, 1-3, 1-4, and 1-5, respectively.

[0044] Figure 4F Phasing and prephasing metrics over 1 x 300 cycles using a spiking mixture with ffA nucleotides labeled with chromanoquinoline dyes 1-1, 1-2, 1-3, 1-4, and 1-5 are shown. DETAILED DESCRIPTION

[0045] Embodiments of the present disclosure relate to chromenoquinoline dyes with enhanced fluorescence intensity, long Stokes shift, and improved chemical stability (particularly in high pH aqueous environments). These chromenoquinoline dyes also have a wide excitation wavelength and can be excited by both a blue light source and a green light source. In some embodiments, the chromenoquinoline dyes described herein can be used in Illumina's iSeq with two-channel CMOS detection (green light excitation and blue light excitation). TM On the platform.

[0046] definition

[0047] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0048] It should be noted that, as used in this specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless expressly and unequivocally limited to one referent. It will be apparent to those skilled in the art that various modifications and variations may be made to the various embodiments described herein without departing from the spirit or scope of the present teachings. Therefore, the various embodiments described herein are intended to cover other modifications and variations within the scope of the appended claims and their equivalents.

[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The use of the term "include" as well as other forms such as "include / includes / included" is not limiting. The use of the term "have" as well as other forms such as "have / has / had" is not limiting. As used in this specification, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning, whether in a transitional phrase or in the body of the claims. That is, the above terms are to be interpreted synonymously with the phrases "at least have" or "at least include". For example, when used in the context of a process, the term "comprising" means that the process includes at least the listed steps, but may also include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the listed features or components, but may also include additional features or components.

[0050] As used herein, common organic abbreviations are defined as follows:

[0051] ℃ Temperature (in degrees Celsius)

[0052] dATP deoxyadenosine triphosphate

[0053] dCTP deoxycytidine triphosphate

[0054] dGTP deoxyguanosine triphosphate

[0055] dTTP deoxythymidine triphosphate

[0056] ddNTP dideoxynucleoside triphosphate

[0057] ffA fully functionalized A nucleotide

[0058] ffC fully functionalized C nucleotide

[0059] ffG fully functionalized G nucleotide

[0060] ffN Fully functionalized nucleotides

[0061] ffT fully functionalized T nucleotide

[0062] h hour

[0063] RT Room temperature

[0064] SBS Sequencing by Synthesis

[0065] As used herein, the term "array" refers to a group of different probe molecules attached to one or more substrates so that these different probe molecules can be distinguished from each other according to relative position. The array may include different probe molecules at different addressable positions on the substrate. Alternatively or additionally, the array may include a separate substrate with different probe molecules, wherein different probe molecules can be identified according to the position of the substrate on the surface to which the substrate is attached or according to the position of the substrate in the liquid. Exemplary arrays in which separate substrates are located on the surface include but are not limited to those comprising beads in holes, such as described in U.S. Patent No. 6,355,431B1, US 2002 / 0102578 and PCT Publication WO 00 / 63437. For example, an exemplary form of beads in liquid arrays, such as using a microfluidic device (such as a fluorescence activated cell sorter (FACS)) to distinguish between the present invention is described in U.S. Patent No. 6,524,793. Additional examples of arrays that can be used in the present invention include, but are not limited to, U.S. Patents 5,429,807; 5,436,327; 5,561,071; 5,583,211; 5,658,734; 5,837,858; 5,874,219; 5,919,523; 6,136,269; 6,287,768; 6,287,776; 6,288,220; 6,297,006; 6,291,193; 6,346,413; 6,416,949; 6,482,591; 6,514,751 and 6,610,482; and WO 93 / 17126; WO 95 / 11995; WO 95 / 35505; EP 742 287; and EP Those described in 799 897.

[0066] As used herein, the term "covalently attached" or "covalently bonded" refers to the formation of a chemical bond characterized by the sharing of electron pairs between atoms. For example, a covalently attached polymer coating refers to a polymer coating that forms a chemical bond with a functionalized surface of a substrate, as opposed to adhering to the surface via other means (e.g., adhesion or electrostatic interactions). It should be understood that a polymer covalently attached to a surface may also be bonded via means other than covalent attachment.

[0067] As used herein, the term "halogen" or "halo" means any of the radioactive stable atoms of column 7 of the periodic table, for example, fluorine, chlorine, bromine or iodine, with fluorine and chlorine being preferred.

[0068] As used herein, "C" wherein "a" and "b" are integers a To C b" refers to the number of carbon atoms in an alkyl, alkenyl, or alkynyl group, or the number of ring atoms in a cycloalkyl or aryl group. That is, the rings of alkyl, alkenyl, alkynyl, cycloalkyl, and aryl groups can contain from "a" to "b" (inclusive) carbon atoms. For example, a "C1 to C4 alkyl" group refers to all alkyl groups having from 1 to 4 carbons, i.e., CH3-, CH3CH2-, CH3CH2CH2-, (CH3)2CH-, CH3CH2CH2 CH2-, CH3CH2CH(CH3)- and (CH3)3C-; C3 to C4 cycloalkyl groups refer to all cycloalkyl groups having 3 to 4 carbon atoms, i.e., cyclopropyl and cyclobutyl. Similarly, a "4 to 6 membered heterocyclyl" group refers to all heterocyclyl groups having 4 to 6 total ring atoms, such as azetidine, oxetane, oxazoline, pyrrolidine, piperidine, piperazine, morpholine, etc. If there is no alkyl, alkenyl, alkynyl, cycloalkyl or aryl group, the alkyl group may be used. If "a" and "b" are specified, the broadest range described in these definitions will be assumed. As used herein, the term "C1-C6" includes C1, C2, C3, C4, C5, and C6, as well as ranges defined by either of these two numbers. For example, C1-C6 alkyl includes C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl, C2-C6 alkyl, C1-C3 alkyl, etc. Similarly, C2-C6 alkenyl includes C2 alkenyl, C3 alkenyl, C4 alkenyl, C5 alkenyl, and C6 alkenyl. C3-C8 cycloalkyl groups include hydrocarbon rings containing 3, 4, 5, 6, 7 and 8 carbon atoms or ranges defined by any two numbers, such as C3-C7 cycloalkyl groups or C5-C6 cycloalkyl groups.

[0069] As used herein, "alkyl" refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., does not contain double bonds and triple bonds). The alkyl group can have 1 to 20 carbon atoms (whenever it appears in this article, a numerical range such as "1 to 20" refers to each integer in the given range; for example, "1 to 20 carbon atoms" means that the alkyl group can be composed of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, but this definition also covers the term "alkyl" in which no numerical range is specified). The alkyl group can also be a medium-sized alkyl group with 1 to 9 carbon atoms. The alkyl group can also be a low alkyl group with 1 to 6 carbon atoms. By way of example only, "C 1-6"Alkyl" or "C1-C6 alkyl" means that there are from one to six carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. Typical alkyl groups include, but are by no means limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.

[0070] As used herein, "alkoxy" refers to a radical of the formula --OR (wherein R is an alkyl radical as defined above), such as "C 1-9 The term "alkoxy" or "C1-C9 alkoxy" includes, but is not limited to, methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, isobutoxy, sec-butoxy and tert-butoxy.

[0071] As used herein, "alkenyl" refers to a straight or branched hydrocarbon chain containing one or more double bonds. An alkenyl group can have from 2 to 20 carbon atoms, but this definition also encompasses the term "alkenyl" where it appears without a specified numerical range. An alkenyl group can also be a medium-sized alkenyl group having from 2 to 9 carbon atoms. An alkenyl group can also be a lower alkenyl group having from 2 to 6 carbon atoms. By way of example only, "C2-C6 alkenyl" or "C 2-6 “Alkenyl” means that there are two to six carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen-1-yl, propen-2-yl, propen-3-yl, buten-1-yl, buten-2-yl, buten-3-yl, buten-4-yl, 1-methyl-propen-1-yl, 2-methyl-propen-1-yl, 1-ethyl-ethen-1-yl, 2-methyl-propen-3-yl, buta-1,3-dienyl, buta-1,2-dienyl and buta-1,2-dien-4-yl. Typical alkenyl groups include, but are by no means limited to, ethenyl, propenyl, butenyl, pentenyl and hexenyl, etc.

[0072] As used herein, "alkynyl" refers to a straight or branched hydrocarbon chain containing one or more triple bonds. An alkynyl group can have from 2 to 20 carbon atoms, but this definition also encompasses the term "alkynyl" where no numerical range is specified. An alkynyl group can also be a medium-sized alkynyl group having from 2 to 9 carbon atoms. An alkynyl group can also be a low-sized alkynyl group having from 2 to 6 carbon atoms. By way of example only, "C 2-6 "Alkynyl" or "C2-C6 alkynyl" means that there are two to six carbon atoms in the alkynyl chain, that is, the alkynyl chain is selected from the group consisting of ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn-3-yl, butyn-4-yl and 2-butynyl. Typical alkynyl groups include, but are by no means limited to, ethynyl, propynyl, butynyl, pentynyl and hexynyl, etc.

[0073] The term "aromatic" refers to a ring or ring system having a conjugated π electron system, and includes both carbocyclic aromatic groups (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine). The term includes monocyclic groups or fused-ring polycyclic (i.e., rings that share adjacent pairs of atoms) groups, provided that the entire ring system is aromatic.

[0074] As used herein, "aryl" refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent carbon atoms) that contains only carbon in the ring backbone. When aryl is a ring system, each ring in the ring system is aromatic. Aryl groups can have 6 to 18 carbon atoms, but this definition also covers the term "aryl" that appears without a specified numerical range. In some embodiments, aryl groups have 6 to 10 carbon atoms. Aryl groups can be designated as "C6-C 10 Aryl", "C6 or C 10 Examples of aryl groups include, but are not limited to, phenyl, naphthyl, azulenyl, and anthracenyl.

[0075] "Aralkyl" or "arylalkyl" is an aryl group attached as a substituent through an alkylene group, such as "C 7-14 "Aralkyl" and the like, including but not limited to benzyl, 2-phenylethyl, 3-phenylpropyl and naphthylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1-6 alkylene group).

[0076] As used herein, "heteroaryl" refers to an aromatic ring or ring system (i.e., two or more condensed rings sharing two adjacent atoms) containing one or more heteroatoms (i.e., elements other than carbon, including but not limited to nitrogen, oxygen and sulfur) in the ring skeleton. When heteroaryl is a ring system, each ring in the ring system is aromatic. The heteroaryl group can have 5 to 18 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring skeleton), but the present definition also encompasses the term "heteroaryl" in which no numerical range is specified. In some embodiments, the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members. The heteroaryl group can be named "5 to 7 yuan heteroaryl", "5 to 10 yuan heteroaryl" or similar names. Examples of heteroaryl rings include, but are not limited to, furanyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolyl, isoquinolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothiophenyl.

[0077] "Heteroaralkyl" or "heteroarylalkyl" is a heteroaryl group attached as a substituent via an alkylene group. Examples include, but are not limited to, 2-thienylmethyl, 3-thienylmethyl, furanylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl. In some cases, the alkylene group is a lower alkylene group (i.e., C 1-6 alkylene group).

[0078] As used herein, "carbocyclyl" means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system skeleton. When the carbocyclyl is a ring system, two or more rings can be joined together in a fused, bridged or spiro manner. The carbocyclyl can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. Therefore, carbocyclyl includes cycloalkyl, cycloalkenyl and cycloalkynyl. The carbocyclyl group can have 3 to 20 carbon atoms, but this definition also covers the term "carbocyclyl" in which no numerical range is specified. The carbocyclyl group can also be a medium-sized carbocyclyl with 3 to 10 carbon atoms. The carbocyclyl group can also be a carbocyclyl with 3 to 6 carbon atoms. The carbocyclyl group can be named "C 3-6 "C3-C6 carbocyclyl", "C3-C6 carbocyclyl" or similar designations. Examples of carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3-dihydro-indene, bicyclo[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.

[0079] As used herein, "cycloalkyl" means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0080] As used herein, "heterocyclyl" refers to a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. The heterocyclyl group can be joined together in a fused, bridged or spiro manner. The heterocyclyl group can have any degree of saturation, provided that at least one ring in the ring system is not aromatic. The heteroatom can be present in a non-aromatic ring or an aromatic ring in the ring system. The heterocyclyl group can have 3 to 20 ring members (i.e., the number of atoms (including carbon atoms and heteroatoms) constituting the ring backbone), but this definition also covers the term "heterocyclyl" in which no numerical range is specified. The heterocyclyl group can also be a medium-sized heterocyclyl group with 3 to 10 ring members. The heterocyclyl group can also be a heterocyclyl group with 3 to 6 ring members. The heterocyclyl group can be named "3 to 6-membered heterocyclyl" or similar names. In preferred six-membered monocyclic heterocyclyls, the heteroatoms are selected from one to a maximum of three from O, N or S, and in preferred five-membered monocyclic heterocyclyls, the heteroatoms are selected from one or two heteroatoms selected from O, N or S. Examples of heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidinedionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxinyl, 1,4-dioxinyl, 1,4-dioxinyl, 1,3-oxathianyl, 1,4-oxathianyl, 1,4-oxathianyl, 2 H-1,2-oxazinyl, trioxanyl, hexahydro-1,3,5-triazinyl, 1,3-dioxolyl, 1,3-dioxolanyl, 1,3-dithienyl, 1,3-dithianyl, isoxazolinyl, isoxazolidinyl, oxazolinyl, oxazolidinyl, oxazolidinone, thiazolinyl, thiazolidinyl, 1,3-oxathiolanyl, indolinyl, isoindolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydrothiopyranyl, tetrahydro-1,4-thiazinyl, thiomorpholinyl, dihydrobenzofuranyl, benzimidazolidinyl and tetrahydroquinoline.

[0081] As used herein, "alkoxyalkyl" or "(alkoxy)alkyl" refers to an alkoxy group attached through an alkylene group, such as C2-C8alkoxyalkyl or (C1-C6alkoxy)C1-C6alkyl, for example -(CH2) 1-3 -OCH3.

[0082] An "O-carboxyl" group is one in which R is selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10Aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl "-OC(=O)R" groups are as defined herein.

[0083] A "C-carboxyl" group is one in which R is selected from the group consisting of hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10 The "-C(=O)OR" group of the group consisting of aryl, 5- to 10-membered heteroaryl, and 3- to 10-membered heterocyclyl, as defined herein. Non-limiting examples include carboxyl (ie, -C(=O)OH).

[0084] A "sulfonyl" group is a group in which R is selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10 The "-SO2R" group of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclyl are as defined herein.

[0085] A "sulfinyl" group refers to a "-S(=O)OH" group.

[0086] A "sulfo" group refers to a "-S(=O)2OH" or a "-SO3H" group.

[0087] A "sulfonate" group refers to a "-SO3-" group.

[0088] A "sulfate" group refers to a "-SO4-" group.

[0089] An "S-sulfonamido" group is one in which R A and R B are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10 "-SO2NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.

[0090] An "N-sulfonamido" group is one in which R A and R b are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10"-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )SO2R B " group, as defined herein.

[0091] A "C-amido" group is one in which R A and R B are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10 "-C(=O)NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein.

[0092] An "N-amido" group is one in which R A and R B are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10 "-N(R)" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A )C(=O)R B " group, as defined herein.

[0093] An "amino" group is one in which R A and R B are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Carbocyclic group, C 6-10 "-NR" of aryl, 5- to 10-membered heteroaryl and 3- to 10-membered heterocyclic group A R B " group, as defined herein. Non-limiting examples include free amino groups (ie, -NH2).

[0094] An "aminoalkyl" group refers to an amino group attached through an alkylene group.

[0095] An "alkoxyalkyl" group refers to an alkoxy group attached through an alkylene group, such as "C2-C8 alkoxyalkyl" and the like.

[0096] When a group is described as "optionally substituted", it can be unsubstituted or substituted. Similarly, when a group is described as "substituted", the substituent can be selected from one or more of the indicated substituents. As used herein, the substituted group is derived from an unsubstituted parent group in which there is an exchange of one or more hydrogen atoms with another atom or group. Unless otherwise specified, when a group is considered to be "substituted", it means that the group is replaced by one or more substituents, which are independently selected from: C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl, C3-C7 carbocyclyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), C3-C7 carbocyclyl-C1-C6-alkyl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3 to 10 C1-C6-alkyl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 3- to 10-membered heterocyclyl-C1-C6-alkyl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), aryl (optionally substituted with halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 5- to 10-membered heteroaryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), 5- to 10-membered heteroaryl (optionally substituted with halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl and C1-C6 haloalkoxy), halo, -CN, hydroxy, C1-C6 alkoxy, C1-C6 alkoxy(C1-C6)alkyl (i.e., ether), aryloxy, sulfhydryl (mercapto) , halo(C1-C6)alkyl (e.g., –CF3), halo(C1-C6)alkoxy (e.g., –OCF3), C1-C6alkylthio, arylthio, amino, amino(C1-C6)alkyl, nitro, O-carbamoyl, N-carbamoyl, O-thiocarbamoyl, N-thiocarbamoyl, C-acylamino, N-acylamino, S-sulfonylamino, N-sulfonylamino, C-carboxyl, O-carboxyl, acyl, cyanate, isocyanate, thiocyanate, isothiocyanate, sulfinyl, sulfonyl, -SO3H, sulfonate, sulfate, sulfinic acid, -OSO2C 1-C4 alkyl and oxo (=O). Wherever a group is described as "optionally substituted", the group may be substituted with the above substituents. In some embodiments, when an alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group is substituted, each of them is independently substituted with one or more substituents selected from the group consisting of: halo, -CN, -SO3 - 、-OSO3 - 、-SO3H、-SR A 、-OR A 、-NR B R C , oxo, -CONR B R C 、-SO2NR B R C , -COOH and -COOR B , where R A , R B and R C Each is independently selected from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, and substituted aryl.

[0097] As will be appreciated by those of ordinary skill in the art, the compounds described herein may exist in an ionized form, for example, -CO2 - 、-SO3 - or –O-SO3-. If the compound contains a positively or negatively charged substituent group, e.g., –SO3 - , it may also contain negatively or positively charged counterions so that the compound is neutral as a whole. In other aspects, the compound may exist in the form of a salt, wherein the counterion is provided by a conjugate acid or base.

[0098] It is understood that certain group naming conventions may include either a monoradical or a diradical, depending on the context. For example, when a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a diradical. For example, a substituent identified as an alkyl group requiring two points of attachment includes a diradical, such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other group naming conventions clearly indicate that the group is a diradical, such as "alkylene" or "alkenylene".

[0099] When two "adjacent" R groups are said to form a ring "together with the atoms to which they are attached", this means that the collection of atoms, intervening bonds, and the two R groups is the ring. For example, when the following substructure is present:

[0100]

[0101] And R1 and R 2 is defined as being selected from the group consisting of hydrogen and alkyl, or R 1 and R 2 Together with the atoms to which they are attached, they form an aryl or carbocyclic group, which means that R 1 and R 2 may be selected from hydrogen or alkyl, or alternatively, the substructure has the structure:

[0102]

[0103] wherein A is an aromatic ring or a carbocyclic group containing a double bond as depicted.

[0104] When a substituent is described as a diradical (i.e., having two points of attachment to the rest of the molecule), it is understood that the substituent may be attached in any orientation unless otherwise indicated. Thus, for example, a substituent depicted as -AE- or Substituents of include those oriented so that A is attached at the leftmost point of attachment of the molecule, as well as substituents in which A is attached at the rightmost point of attachment of the molecule. In addition, if a group or substituent is depicted as Then L is defined as an optionally present linker moiety; when L is absent (or missing), such group or substituent is equivalent to

[0105] In each case where a single meso form of a compound described herein is shown, the alternative meso forms are also contemplated.

[0106] As used herein, "nucleotides" include nitrogenous heterocyclic bases, sugars, and one or more phosphate groups. They are monomeric units of nucleic acid sequences. In RNA, the sugar is ribose, and in DNA it is deoxyribose, i.e., a sugar lacking the hydroxyl groups present in ribose. The nitrogenous heterocyclic bases may be purines, deazapurines, or pyrimidine bases. Purine bases include adenine (A) and guanine (G) and their modified derivatives or analogs, such as 7-deazaadenine or 7-deazaguanine. Pyrimidine bases include cytosine (C), thymine (T), and uracil (U) and their modified derivatives or analogs. The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.

[0107] As used herein, "nucleoside" is structurally similar to a nucleotide, but lacks a phosphate moiety. An example of a nucleoside analog is a nucleoside analog in which a label is attached to a base and no phosphate group is attached to a sugar molecule. The term "nucleoside" is used herein in the conventional sense as understood by those skilled in the art. Examples include, but are not limited to, ribonucleosides comprising a ribose moiety and deoxyribonucleosides comprising a deoxyribose moiety. A modified pentose moiety is a pentose moiety in which an oxygen atom has been replaced by a carbon and / or a carbon has been replaced by a sulfur or oxygen atom. A "nucleoside" is a monomer that may have a substituted base and / or sugar moiety. In addition, nucleosides may be incorporated into larger DNA and / or RNA polymers and oligomers.

[0108] The term "purine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. Similarly, the term "pyrimidine base" is used herein with the common meaning understood by those skilled in the art, and includes its tautomers. The non-limiting list of optionally substituted purine bases includes purine, adenine, guanine, deazapurine, 7-deazaadenine, 7-deazaguanine, hypoxanthine, xanthine, alloxanthine, 7-alkylguanine (e.g., 7-methylguanine), theobromine, caffeine, uric acid, and isoguanine. The example of pyrimidine bases includes, but is not limited to, cytosine, thymine, uracil, 5,6-dihydrouracil, and 5-alkylcytosine (e.g., 5-methylcytosine).

[0109] As used herein, when oligonucleotide or polynucleotide are described as "comprising " nucleoside or nucleotide as described herein, this means that nucleoside or nucleotide as described herein forms covalent bond with oligonucleotide or polynucleotide.Similarly, when nucleoside or nucleotide are described as a part of oligonucleotide or polynucleotide, such as "being incorporated into " oligonucleotide or polynucleotide, this means that nucleoside or nucleotide as described herein forms covalent bond with oligonucleotide or polynucleotide.In some such embodiments, covalent bond is formed between 5' phosphate groups of the nucleotide of phosphodiester bond between 3' carbon atom of oligonucleotide or polynucleotide and 5' carbon atom of nucleotide described in this article.

[0110] As used herein, the term "cleavable linker" is not intended to imply that the entire linker needs to be removed. The cleavage site can be located at a position on the linker that ensures that a portion of the linker remains attached to the detectable label and / or nucleoside or nucleotide moiety after cleavage.

[0111] As used herein, "derivative" or "analog" means a synthetic nucleotide or nucleoside derivative with a modified base moiety and / or a modified sugar moiety. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide Analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs can also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphate bonds and phosphoramidate bonds. As used herein, "derivative", "analog" and "modified" can be used interchangeably, and are covered by the terms "nucleotide" and "nucleoside" defined herein.

[0112] As used herein, the term "phosphate" is used with the ordinary meaning understood by those skilled in the art and includes its protonated form (e.g., ). As used herein, the terms "monophosphate," "diphosphate," and "triphosphate" are used with their ordinary meaning as understood by those skilled in the art, and include protonated forms.

[0113] As used herein, the term "phasing" refers to a phenomenon in SBS, which is caused by the incomplete removal of 3' terminators and fluorophores and / or failure to complete the incorporation of a portion of the DNA chain in the cluster by polymerase under a given sequencing cycle. Prephasing is caused by the incorporation of nucleotides that do not have an effective 3' terminator, wherein the incorporation event is advanced by 1 cycle due to termination failure. Phasing and prephasing cause the measured signal intensity of a specific cycle to be composed of the signal from the current cycle and the noise from the previous and next cycles. As the number of cycles increases, the sequence score of each cluster affected by phasing and prephasing increases, hindering the identification of the correct base. Prephasing can be caused by the presence of traces of unprotected or uncapped 3'-OH nucleotides during sequencing by synthesis (SBS). Unprotected 3'-OH nucleotides can be produced during the manufacturing process or may be stored and during the reagent handling process. Therefore, the discovery of nucleotide analogs that reduce the incidence of prephasing is surprising, and relative to existing nucleotide analogs, provides a huge advantage in SBS applications. For example, the provided nucleotide analogs can produce faster SBS cycle times, lower phasing and prephasing values, and longer sequencing read lengths.

[0114] Chromenoquinoline dyes of formula (I)

[0115] Some aspects of the present disclosure relate to chromenoquinoline dyes of formula (I) and their salts and meso forms:

[0116]

[0117] Where R 1 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12a and R 12b each of which is independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, (C1-C6 alkoxy)C1-C6 alkyl, optionally substituted amino, amino(C1-C6 alkyl), halo, cyano, hydroxy, hydroxy(C1-C6 alkyl), nitro, sulfonyl, sulfo, sulfinyl, sulfonate, S-sulfonamido, or N-sulfonamido;

[0118] R 2 and R 3 Each of is independently H, C1-C6 alkyl or substituted C1-C6 alkyl; and

[0119] R 6 is C1-C6 alkyl or substituted C1-C6 alkyl;

[0120] Alternatively, R 1 and R 2 together with the atoms to which they are attached form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 5- to 10-membered heterocyclyl; and / or

[0121] Alternatively, R 3 and R 4 together with the atoms to which they are attached form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 5- to 10-membered heterocyclyl; and / or

[0122] Alternatively, R 8 and R 9 Together with the atoms to which they are attached, they form an optionally substituted C6-C 10 aryl, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocyclyl;

[0123] The prerequisite is that when R 2 and R 3 Each of R is ethyl; 1 , R 4 , R 5 , R 7 , R 8 , R10 , R 11 , R 12a and R 12b Each of is H; and R 6 When it is methyl, then R 9 is a substituted C1-C6 alkyl group containing a carboxyl group; and

[0124] The prerequisite is that when R 1 and R 2 Together with the atoms to which they are attached, they form a piperidinyl group, and R 3 and R 4 Together with the atoms to which they are attached, they form a piperidinyl group, giving the compound the structure R 5 , R 7 , R 8 , R 10 , R 11 , R 12a and R 12b Each of is H; and R 6 When it is methyl, then R 9 It is a substituted C1-C6 alkyl group containing a carboxyl group.

[0125] In any embodiment of the compound of formula (I), when the group is defined as substituted C1-C6 alkyl, it can be substituted by carboxyl, carboxylate, sulfonate, sulfonate, -C(O)OR 15 or –C(O)NR 16 R 17 substituted C1, C2, C3, C4, C5 or C6 alkyl, and wherein each R 16 and R 17 are independently H or substituted by carboxyl, carboxylate, -C(O)OR 15 , sulfonyl or sulfonate substituted C1-C6 alkyl.

[0126] In some embodiments of the compound of Formula (I), R 2 and R 3 At least one of is H. In some other embodiments, R 2 and R 3 are all H. In other embodiments, R 2 is H, and R 3 is C1-C6 alkyl or substituted C1-C6 alkyl. In other embodiments, R 2 and R 3Each of the above is independently a C1-C6 alkyl or a substituted C1-C6 alkyl. Substituted C1-C6 alkyl includes, but is not limited to, methyl, ethyl, isopropyl, n-propyl, n-butyl, 2-butyl, n-pentyl, 2-pentyl, n-hexyl, etc., which are substituted by one or more substituents such as carboxyl, carboxylate (-C(O)O - ), sulfonic acid (-SO3H), sulfonic acid (-SO3 - ), sulfate (–O-SO3 - ), optionally substituted amino (such as Boc protected amino group), -C(O)OR 15 or –C(O)NR 16 R 17 , where R 15 is an optionally substituted C1-C6 alkyl, an optionally substituted C6-C 10 aryl, optionally substituted 5- to 10-membered heteroaryl or optionally substituted C3-C7 cycloalkyl, and wherein R 16 and R 17 Each of the following is independently H, optionally substituted C1-C6 alkyl, optionally substituted C6-C 10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted C3-C7 cycloalkyl. 2 and R 3 In another embodiment, each of R 2 is H, and R 3 It is a propyl group substituted by a carboxyl group.

[0127] In any embodiment of the compound of formula (I), when the group is defined as substituted C1-C6 alkyl, it can be substituted by carboxyl, carboxylate, sulfonate, sulfonate, -C(O)OR 15 or –C(O)NR 16 R 17 substituted C1, C2, C3, C4, C5 or C6 alkyl, and wherein each R 16 and R 17 are independently H or substituted by carboxyl, carboxylate, -C(O)OR 15 , sulfonyl or sulfonate substituted C1-C6 alkyl.

[0128] Some embodiments of compounds of formula (I) are also represented by formula (Ia), wherein R 3 and R 4 Together with the atoms to which they are attached, they form an optionally substituted 6-membered heterocyclyl having the structure:

[0129] Its salts or meso forms:

[0130] Where R 13a , R 13b , R 14a and R 14b each of which is independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, (C1-C6 alkoxy)C1-C6 alkyl, optionally substituted amino, amino(C1-C6 alkyl), halo, cyano, hydroxy, hydroxy(C1-C6 alkyl), nitro, sulfonyl, sulfo, sulfinyl, sulfonate, S-sulfonamido, or N-sulfonamido; and

[0131] By solid and dotted lines The bond represented by is selected from the group consisting of single bonds and double bonds, provided that when When it is a double bond, R 14b Does not exist.

[0132] In some embodiments of the compound of Formula (Ia), the solid and dashed lines The bond represented by is a double bond. In some such embodiments, R 14a is H or C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, n-propyl, n-butyl, 2-butyl, n-pentyl, 2-pentyl or n-hexyl, etc.). In one embodiment, R 14a In other embodiments of the compound of formula (Ia), the solid and dashed lines The bond represented by is a single bond. In some such embodiments, R 14a is H, and R 14b is C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, n-propyl, n-butyl, 2-butyl, n-pentyl, 2-pentyl or n-hexyl, etc.). In some such embodiments, R 14a and R 14b Each of is H. In some embodiments, R 13a and R 13b Each of is H. In other embodiments, R 13a and R 13b Each of is C1-C6 alkyl. In one embodiment, R 13a and R 13b Each of is methyl.

[0133] In some embodiments of the compound of Formula (Ia), R 2 is H. In other embodiments, R 2is C1-C6 alkyl or substituted C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, n-propyl, n-butyl, 2-butyl, n-pentyl, 2-pentyl or n-hexyl, etc.). In some other embodiments, R 2 is a C1-C6 alkyl group substituted by one or more substituents selected from the group consisting of carboxyl (-C(O)OH), carboxylate (-C(O)O - ), sulfonic acid (–SO3H), sulfonic acid (–SO3 - ),–C(O)OR 15 and –C(O)NR 16 R 17 , where R 15 is an optionally substituted C1-C6 alkyl, an optionally substituted C6-C 10 aryl, optionally substituted 5- to 10-membered heteroaryl or optionally substituted C3-C7 cycloalkyl, and wherein R 16 and R 17 Each of the following is independently H, optionally substituted C1-C6 alkyl, optionally substituted C6-C 10 In some other embodiments, R 2 is carboxyl or –C(O)NR 16 R 17 substituted C1-C6 alkyl, and wherein each R 16 and R 17 are independently carboxy, carboxylate, –C(O)OR 15 In some embodiments, the substitution is at the end of a straight chain C2 alkyl, C3 alkyl, C5 alkyl, C6 alkyl or C6 alkyl. In one embodiment, R 3 It is a propyl group substituted by a carboxyl group.

[0134] In some embodiments of the compound of Formula (I) or (Ia), R 1 is H. In other embodiments, R 1 and R 2 are joined together with the atoms to which they are attached to form an optionally substituted 5-membered, 6-membered, or 7-membered heterocyclyl. 1 and R 2 Together with the atoms to which they are attached, they form a 6-membered heterocyclic group substituted with one or more C1-C6 alkyl groups.

[0135] In some embodiments of the compound of Formula (I) or Formula (Ia), R 6 is C1-C6 alkyl. In one embodiment, R 6In other embodiments, R 6 is carboxyl or –C(O)NR 16 R 17 substituted C1-C6 alkyl, and wherein each R 16 and R 17 are independently carboxy, carboxylate, –C(O)OR 15 , sulfonyl or sulfonate substituted C1-C6 alkyl.

[0136] In some embodiments of the compound of Formula (I) or Formula (Ia), R 5 is H. In some additional embodiments, R 11 is H. In some additional embodiments, R 12a and R 12b Each of is H.

[0137] In some embodiments of the compound of Formula (I) or (Ia), R 7 , R 8 R 9 and R 10 At least one of is H. In one such embodiment, R 7 , R 8 , R 9 and R 10 In another such embodiment, each of R 7 , R 8 and R 10 In another such embodiment, each of R 7 and R 10 is H. In other embodiments, R 7 , R 8 , R 9 and R 10 At least one of R is independently C1-C6 alkyl (e.g., methyl, ethyl, isopropyl, n-propyl, n-butyl, 2-butyl, n-pentyl, 2-pentyl or n-hexyl, etc.) or C1-C6 alkoxy (e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, n-pentoxy, 2-pentyloxy, n-hexyl, etc.). In one such embodiment, R 9 In another such embodiment, R 8 and R 9 In yet another embodiment, each of R 8 , R 9 and R 10 In other embodiments, each of R 7 , R 8 , R9 and R 10 At least one of them is a C1-C6 alkyl-substituted carboxyl, carboxylate, sulfonate, sulfonate, -C(O)OR 15 or –C(O)NR 16 R 17 , and each R 16 and R 17 are independently H or substituted by carboxyl, carboxylate, –C(O)OR 15 In other embodiments, R 8 and R 9 Together with the atoms to which they are attached, they form an optionally substituted 5- or 6-membered heterocyclyl, such as those having structures such as:

[0138] Additional embodiments of compounds of formula (I) or (Ia) include the following:

[0139] and their salts and meso forms. Non-limiting examples are the corresponding C1-C6 alkyl carboxylates (such as methyl, ethyl, isopropyl and tert-butyl esters formed from the carboxyl group of the compound).

[0140] Cyclooctatetraene (COT) photoprotective moiety

[0141] In some embodiments, the fluorescent compounds described herein (Formula (I) or (Ia)) can be further modified to introduce photoprotective moieties covalently bonded thereto, for example, cyclooctatetraene moieties including the structure in

[0142] R 1A and R 2A Each of the following is independently H, hydroxy, halo, azido, thiol, nitro, cyano, optionally substituted amino, carboxyl, -C(O)OR 5A 、-C(O)NR 6A R 7A , optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 haloalkoxy, optionally substituted C 2-6 Alkenyl, optionally substituted C 2-6 Alkynyl, optionally substituted C 6-10 Aryl, optionally substituted C 7-14 Arylalkyl, optionally substituted C 3-7carbocyclyl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocyclyl;

[0143] X 1 and Y 1 are each independently a bond, -O-, -S-, -NR 3A -, -C(=O)-, -C(=O)-O-, -C(=O)-NR 4A -、-S(O)2-、-NR 3A -C(=O)-NR 4A 、-NR 3A -C(=S)-NR 4A -, optionally substituted C 1-6 alkylene or optionally substituted heteroalkylene, wherein at least one carbon atom is substituted by O, S or N;

[0144] Z is absent and is optionally substituted C 2-6 Alkenylene or optionally substituted C 2-6 Alkyne;

[0145] R 3A and R 4A Each of which is independently H, optionally substituted C 1-6 Alkyl or optionally substituted C 6-10 Aryl;

[0146] R 5A is optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl, optionally substituted C 7-14 Arylalkyl, optionally substituted C 3-7 carbocyclyl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocyclyl;

[0147] R 6A and R 7A Each of which is independently H, optionally substituted C 1-6 Alkyl, optionally substituted C 6-10 Aryl, optionally substituted C 7-14 Arylalkyl, optionally substituted C 3-7 carbocyclyl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocyclyl;

[0148] exist Medium R 1A and R 2A The carbon atom to which it is attached is optionally substituted with O, S or N, provided that when the carbon atom is substituted with O or S, then R 1A and R 2ANeither of them exists; when the carbon atom is replaced by N, then R 2A is absent; and m is an integer between 0 and 10. In some embodiments, neither X nor Y is a bond.

[0149] In some embodiments, the cyclooctatetraene moiety comprises the structure In some such embodiments, R 1A and R 2A In some other embodiments, at least one of R 1A and R 2A Both are hydrogen. In some other embodiments, R 1A is H and R 2A is optionally substituted amino, carboxyl or -C(O)NR 6A R 7A In some embodiments, m is 1, 2, 3, 4, 5 or 6, and R 1A and R 2A Each of the following is independently hydrogen, optionally substituted amino, carboxyl, -C(O)NR 6A R 7A or a combination thereof. In some further embodiments, when m is 2, 3, 4, 5 or 6, one R 1A is amino, carboxyl or -C(O)NR 6A R 7A , and the rest R 1A and R 2A is hydrogen. In some embodiments, Medium R 1A and R 2A At least one of the carbon atoms to which it is attached is substituted with O, S, or N. In some such embodiments, One of the carbon atoms in is replaced by an oxygen atom, and R attached to the replaced carbon atom 1A and R 2A In some other embodiments, when When one of the carbon atoms in is replaced by a nitrogen atom, the R 2A is not present and is attached to the substituted carbon atom R 1A is hydrogen or C 1-6 Alkyl. In R 1A and R 2A In any embodiment of the present invention, when R 1A or R 2A Yes-C(O)NR 6A R 7A When R 6A and R 7A Can be H, C independently 1-6Alkyl or substituted C 1-6 Alkyl (e.g., -CO2H, -NH2, -SO3H or -SO3 - Substituted C 1-6 alkyl).

[0150] In some additional embodiments, the fluorescent dyes described herein comprise a cyclooctatetraene moiety of the following structure:

[0151] The COT moieties described herein can result from the reaction between a functional group (eg, a carboxyl group) of a fluorescent dye described herein and an amino group of a COT derivative to form an amide bond (wherein the carbonyl group of the amide bond is not shown).

[0152] Labeled nucleotides or oligonucleotides

[0153] According to one aspect of the present disclosure, dye compound as described herein is applicable to be attached to substrate part, particularly comprises linker group so that it is possible to attach to the dye compound of substrate part.Substrate part can in fact be any molecule or material that dye of the present disclosure can be put together with it, and in the manner of non-limiting example, can include nucleosides, nucleotides, polynucleotides, carbohydrates, ligands, particles, solid surfaces, organic polymers and inorganic polymers, chromosomes, cores, living cells, and their combinations or assemblies.Dye can be put together by various means (including hydrophobic attraction, ion attraction and covalent connection) by optional linker.In some respects, dye is put together to substrate by covalent attachment.More specifically, covalent connection is realized by means of linker group.In some cases, the nucleotide of such labeling is also referred to as " modified nucleotide ".

[0154] Some aspects of the present disclosure relate to nucleotides or oligonucleotides labeled with a dye of formula (I) or formula (Ia) as described herein or a salt of its meso form, or a derivative thereof containing a light protection moiety COT as described herein. The labeled nucleotides or oligonucleotides can be attached to dye compounds disclosed herein to form amides or alkyl-amide bonds via carboxyl (-CO2H) or alkyl-carboxyl groups. In some other embodiments, the carboxyl group can be in the form of an activated form of a carboxyl group, such as an amide or ester, which can be used to connect to an amino or hydroxyl group of a nucleotide or oligonucleotide. The term "activated ester" as used herein refers to a carboxyl group derivative that can react with, for example, a compound containing an amino group under mild conditions. Non-limiting examples of activated esters include, but are not limited to, p-nitrophenyl, pentafluorophenyl, and succinimide esters.

[0155] For example, the dye compound of formula (I) can be obtained by 6 , R 7 , R8 , R 9 , R 10 and R 11 One of or R 2 / R 3 In some such embodiments, R of formula (I) 9 Contains -CO2H or -(CH2) 1-6 -CO2H, and the attachment is at R 9 The amide portion is formed between the carboxyl functional group of the nucleotide or the amino functional group of the nucleotide or nucleotide linker. As an example, the labeled nucleotide or oligonucleotide may include a dye portion having the following structure:

[0156] In other embodiments, R of formula (I) 2 or R 3 Contains -CO2H or -(CH2) 1-6 -CO2H, and the attachment uses the –CO2H group to form an amide. For example, a labeled nucleotide or oligonucleotide may contain the following dye moieties:

[0157]

[0158] Similarly, the dye compound of formula (Ia) can be obtained via R 6 , R 7 , R 8 , R 9 , R 10 and R 11 One of (e.g., R 9 ) or R 2 , attached to a nucleotide or oligonucleotide by forming an amide moiety between the carboxyl functional group of the compound and the amino functional group of the nucleotide or nucleotide linker. For example, a labeled nucleotide or oligonucleotide may comprise the following dye moieties:

[0159] In other embodiments, R of Formula (I) or Formula (Ia) 6 Including -CO2H or -(CH2) 1-6 -CO2H, and this linkage forms an amide using the –CO2H group.

[0160] In some embodiments, dye compound can be covalently attached to oligonucleotide or nucleotide via nucleotide base.In some such embodiments, the nucleotide or oligonucleotide of labeling can have the dye of C5 position or C7 position of 7-deazapurine base optionally attached to pyrimidine base by connecting base part.For example, core base can be 7-deazaadenine, and dye is optionally connected to 7-deazaadenine by connecting base at C7 position.Core base can be 7-deazaguanine, and dye is optionally connected to C7 position of 7-deazaguanine by connecting base.Core base can be cytosine, and dye is optionally connected to C5 position of cytosine by connecting base.As another example, core base can be thymine or uracil, and dye is optionally attached to thymine or uracil by connecting base at C5 position.

[0161] 3' Hydroxyl Capping Group

[0162] The nucleotide or oligonucleotide of labeling can also have the capping group of the ribose or deoxyribose of nucleotide covalently connected.This capping group can be connected at any position on ribose or deoxyribose.In a particular embodiment, this capping group is located at the 3'OH position of the ribose or deoxyribose of nucleotide.Various 3'OH capping groups are disclosed in WO2004 / 018497 and WO2014 / 139596, and these applications are hereby incorporated by reference.For example, the capping group can be azidomethyl (-CH2N3) or substituted azidomethyl (for example, -CH(CHF2)N3 or CH(CH2F)N3), or the allyl group of the 3' oxygen atom connected to ribose or deoxyribose moiety.In some embodiments, 3' capping group is azidomethyl, forms 3'-OCH2N3 with the 3' carbon of ribose or deoxyribose.

[0163] In some other embodiments, the 3' capping group and the 3' oxygen atom form a structure covalently attached to the 3' carbon of ribose or deoxyribose. An acetal group, wherein:

[0164] R 1a and R 1b Each independently is H, C1-C6 alkyl, C 1- C6 haloalkyl, C 1- C6 alkoxy, C 1- C6 haloalkoxy, cyano, halogen, optionally substituted phenyl or optionally substituted aralkyl;

[0165] R 2a and R 2b Various independently H, C 1- C6 alkyl, C 1- C6 haloalkyl, cyano or halogen;

[0166] Alternatively, R 1a and R 2a together with the atoms to which they are attached form an optionally substituted five- to eight-membered heterocyclyl group;

[0167] R F is H, optionally substituted C2-C6 alkenyl, optionally substituted C3-C7 cycloalkenyl, optionally substituted C2-C6 alkynyl or optionally substituted (C1-C6 alkylene)Si(R 3a )3; and

[0168] Each R 3a Independently H, C 1- C6 alkyl or optionally substituted C 6- C 10 Aryl.

[0169] Additional 3'OH capping groups are disclosed in U.S. Publication No. 2020 / 0216891 A1, which is incorporated by reference in its entirety. Non-limiting examples of acetal capping groups are (AOM), Each is covalently attached to the 3' carbon of ribose or deoxyribose.

[0170] 3' Deprotection of hydroxyl end groups

[0171] In some embodiments, the azidomethyl 3' hydroxy protecting group can be removed or deprotected by using a water-soluble phosphine reagent. Non-limiting examples include tris(hydroxymethyl)phosphine (THMP), tris(hydroxyethyl)phosphine (THEP), or tris(hydroxypropyl)phosphine (THP or THPP). The 3'-acetal capping groups described herein can be removed or cleaved under various chemical conditions. For acetal capping groups containing vinyl or alkenyl moieties, Non-limiting cleavage conditions include Pd (II) complexes such as Pd (OAc) 2 or allyl chloride Pd (II) dimers in the presence of a phosphine ligand, e.g., tris (hydroxymethyl) phosphine (THMP) or tris (hydroxypropyl) phosphine (THP or THPP). For those end-capping groups containing alkynyl groups (e.g., ethynyl), they can also be removed by Pd (II) complexes (e.g., Pd (OAc) 2 or allyl chloride Pd (II) dimers) in the presence of a phosphine ligand (e.g., THP or THMP).

[0172] Palladium cleavage reagent

[0173] In some embodiments, the 3' hydroxyl end-capping group described herein can be cleaved by a palladium catalyst. In some such embodiments, the Pd catalyst is water-soluble. In some such embodiments, it is a Pd(0) complex (e.g., tris(3,3′,3″-phosphinyltri(benzenesulfonate)palladium(0) nonahydrate). In some cases, the Pd(0) complex can be generated in situ by reducing a Pd(II) complex with a reagent such as an olefin, an alcohol, an amine, a phosphine, or a metal hydride. Suitable palladium sources include Na2PdCl4, Pd(CH3CN)2Cl2, (PdCl(C3H5))2, [Pd(C3H5)(THP)]Cl, [Pd(C3H5)(THP)2]Cl, Pd(OAc)2, Pd(Ph3)4, Pd(dba)2, Pd(Acac)2, PdCl2(COD), and Pd(CH3CN)2Cl2. d(TFA)2. In one such embodiment, the Pd(0) complex is generated in situ from Na2PdCl4. In another embodiment, the palladium source is allylpalladium(II) chloride dimer [(PdCl(C3H5))2]. In some embodiments, the Pd(0) complex is generated in aqueous solution by mixing the Pd(II) complex with a phosphine. Suitable phosphines include water-soluble phosphines such as tri(hydroxypropyl)phosphine (THP), tri(hydroxymethyl)phosphine (THMP), 1,3,5-triaza-7-phosphaadamantane (PTA), bis(p-sulfonic acid phenyl)phenylphosphine dihydrate potassium salt, tri(carboxyethyl)phosphine (TCEP) and triphenylphosphine-3,3',3'-trisulfonic acid trisodium salt.

[0174] In some embodiments, Pd(0) is prepared by mixing a Pd(II) complex [(PdCl(C3H5))2] with THP in situ. The molar ratio of the Pd(II) complex to THP can be about 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10. In some additional embodiments, one or more reducing agents can be added, such as ascorbic acid or a salt thereof (e.g., sodium ascorbate). In some embodiments, the cleavage mixture can contain additional buffer reagents, such as primary amines, secondary amines, tertiary amines, carbonates, phosphates, or borates, or combinations thereof. In some other embodiments, the buffer reagent includes ethanolamine (EA), tris (hydroxymethyl) aminomethane (Tris), glycine, sodium carbonate, sodium phosphate, sodium borate, 2-dimethylethanolamine (DMEA), 2-diethylethanolamine (DEEA), N, N, N', N'-tetramethylethylenediamine (TEMED) or N, N, N', N'-tetraethylethylenediamine (TEEDA), or a combination thereof. In one embodiment, the buffer is DEEA. In another embodiment, the buffer contains one or more inorganic salts, such as carbonates, phosphates or borates, or a combination thereof. In one embodiment, the inorganic salt is a sodium salt.

[0175] Connector

[0176] Dye compounds as disclosed herein can include reactive linker groups at one of the substituent positions for covalently linking the compound to a substrate or another molecule. Reactive linker groups are capable of forming a bond (e.g., covalent or non-covalent bond), particularly a covalent bond. In a specific embodiment, linker groups can be cleavable linkers. The use of the term "cleavable linker" is not intended to imply the need to remove the entire linker. The cleavage site can be located on the linker to ensure that a portion of the linker remains connected to a certain position of the dye and / or substrate portion after cleavage. In a non-limiting example, cleavable linkers can be electrophilic cleavable linkers, nucleophilic cleavable linkers, photocleavable linkers, cleavable under reducing conditions (e.g., linkers containing disulfide or azide), cleavable under oxidative conditions, cleavable by using a secure capture linker, and cleavable by an elimination mechanism. Using a cleavable linker to connect dye compounds to the substrate portion ensures that, if necessary, the label can be removed after detection, thereby avoiding any interfering signal in the downstream step.

[0177] Useful linker groups can be found in PCT Publication WO2004 / 018493 (incorporated herein by reference), examples of which include linkers that can be cleaved using water-soluble phosphines or water-soluble transition metal catalysts formed by transition metals and at least partially water-soluble ligands. In aqueous solutions, the latter form at least partially water-soluble transition metal complexes. Such cleavable linkers can be used to connect the bases of nucleotides to labels, such as dyes described herein.

[0178] Particular linking groups include those disclosed in PCT Publication WO 2004 / 018493 (incorporated herein by reference), such as those comprising a moiety of the formula:

[0179]

[0180] (wherein X is selected from the group consisting of O, S, NH and NQ, wherein Q is a C1-10 substituted or unsubstituted alkyl group, Y is selected from the group consisting of O, S, NH and N (allyl), T is hydrogen or C1-C 10 substituted or unsubstituted alkyl group, and * indicates the position where the moiety is attached to the rest of the nucleotide or nucleoside). In some aspects, the linker connects the base of the nucleotide to a label, such as a dye compound described herein.

[0181] Additional examples of linkers include those disclosed in U.S. Publication No. 2016 / 0040225 (incorporated herein by reference), such as those comprising a moiety of the formula:

[0182]

[0183] (where * indicates the position where the portion is attached to the rest of the nucleotide or nucleoside). The linker moiety presented herein may include all or part of the linker structure between the nucleotide / nucleoside and the label. The linker moiety presented herein may include all or part of the linker structure between the nucleotide / nucleoside and the label.

[0184] Additional examples of linking groups include moieties of the formula:

[0185] Wherein B is a nucleobase; Z is -N3 (azido), -O-C1-C6 alkyl, -O-C2-C6 alkenyl or -O-C2-C6 alkynyl; and F1 includes a dye portion, which may contain an additional linker structure. It is understood by those of ordinary skill in the art that the dye compounds described herein are covalently bonded to the linker by reacting a functional group (e.g., carboxyl) of the dye compound with a functional group (e.g., amino) of the linker. In one embodiment, the cleavable linker comprises ("AOL" linker moiety), wherein Z is -O-allyl.

[0186] In certain embodiments, the length of the linker between the fluorescent dye (fluorophore) and the guanine base can be varied, for example, by introducing a polyethylene glycol spacer group, thereby increasing the fluorescence intensity compared to the same fluorophore attached to the guanine base by other bonds known in the art. Exemplary linkers and their properties are shown in PCT Publication WO2007020457 (incorporated herein by reference). The design of the linker, and particularly its increased length, can allow for improved brightness of the fluorophore attached to the guanine base of a guanosine nucleotide when incorporated into a polynucleotide such as DNA. Thus, when the dye is used in any analytical method requiring detection of a fluorescent dye label attached to a nucleotide containing guanine, it is advantageous for the linker to comprise the formula –((CH2)2O) n - a spacer group wherein n is an integer between 2 and 50 as described in WO 2007 / 020457.

[0187] Nucleoside and nucleotide can be marked at the site on sugar or nucleobase.As known in the art, "nucleotide" is composed of nitrogenous base, sugar and one or more phosphate groups.In RNA, the sugar is ribose, and in DNA it is deoxyribose, that is, the sugar lacking the hydroxyl group present in ribose.Nitrogenous base is a derivative of purine or pyrimidine.Purine is adenine (A) and guanine (G), and pyrimidine is cytosine (C) and thymine (T), or in the case of RNA it is uracil (U).The C-1 atom of deoxyribose is bonded to the N-1 of pyrimidine or the N-9 of purine.Nucleotide is also the phosphate ester of nucleoside, wherein esterification occurs on the hydroxyl group of C-3 or C-5 attached to sugar.Nucleotide is usually monophosphate, diphosphate or triphosphate.

[0188] A "nucleoside" is structurally similar to a nucleotide, but lacks a phosphate moiety. An example of a nucleoside analog is one in which the label is attached to the base and there is no phosphate group attached to the sugar molecule.

[0189] Although bases are commonly referred to as purines or pyrimidines, it will be appreciated by the skilled artisan that derivatives and analogs that do not change the ability of a nucleotide or nucleoside to undergo Watson-Crick base pairing are available. "Derivative" or "analog" means a compound or molecule whose core structure is identical or very similar to that of the parent compound, but which has a chemical or physical modification that allows the derived nucleotide or nucleoside to be connected to another molecule, such as a different or additional side group. For example, the base can be a deazapurine. In a particular embodiment, the derivative should be able to undergo Watson-Crick pairing. "Derivatives" and "analogs" also include, for example, synthetic nucleotides or nucleoside derivatives with modified base moieties and / or modified sugar moieties. Such derivatives and analogs are discussed in, for example, Scheit, Nucleotide analogs (John Wiley & Son, 1980) and Uhlman et al., Chemical Reviews 90: 543-584, 1990. Nucleotide analogs can also include modified phosphodiester bonds, including phosphorothioate bonds, phosphorodithioate bonds, alkylphosphonate bonds, aniline phosphate bonds, phosphoramidate bonds, and the like.

[0190] Dye can be attached to any position on the nucleotide base, for example, by a linker. In a particular embodiment, the analogue obtained can still be subjected to Watson-Crick base pairing. Specific core base labeling sites include the C5 position of pyrimidine bases or the C7 position of 7-deazapurine bases. As mentioned above, a linker group can be used for covalently attaching the dye to a nucleoside or nucleotide.

[0191] In a particular embodiment, the nucleotide or oligonucleotide of the label can be enzymatically incorporated and enzymatically extended. Therefore, the linker portion can have enough length to connect the nucleotide to the compound so that the compound does not significantly interfere with the overall binding and recognition of the nucleic acid replicator to the nucleotide. Therefore, the linker can also include a spacer unit. The spacer distance is, for example, the distance of the nucleotide base from the cleavage site or label.

[0192] Nucleosides or nucleotides labeled with dyes described herein may have the following formula:

[0193]

[0194] wherein the dye is a chromophore quinoline dye compound (label) moiety as described herein (after covalent bonding between the functional group of the dye and the functional group of the linker "L"); B is a nucleobase such as uracil, thymine, cytosine, adenine, 7-deazaadenine, guanine, 7-deazaguanine, etc.; L is an optional linker that may or may not be present; R' may be H, or -OR' is a monophosphate, a diphosphate, a triphosphate, a thiophosphate, a phosphate analog, -O- attached to a reactive phosphorus-containing group, or -O- protected by a capping group; R" is H or OH; and R"' is H, a 3'OH capping group as described herein, or -OR"' forms a phosphoramidite. wherein -OR"' is a phosphoramidite and R' is an acid-cleavable hydroxyl protecting group that allows subsequent monomer coupling under automated synthesis conditions. In some additional embodiments, B comprises Or their optionally substituted derivatives and analogs. In some other embodiments, the labeled nucleobase comprises the structure

[0195] In a particular embodiment, the capping group is separate and independent of the dye compound, i.e., not attached to the latter. Alternatively, the dye may comprise all or part of a 3'-OH capping group. Thus, R"' may be a 3'OH capping group that may or may not constitute a dye compound.

[0196] In yet another alternative embodiment, there is no capping group on the 3' carbon of the pentose, and the dye (or dye and linker configuration) attached to the base can, for example, be of a size or structure sufficient to act as a barrier to the incorporation of additional nucleotides. Thus, the barrier can be due to steric hindrance or can be due to a combination of size, charge, and structure, regardless of whether the dye is attached to the 3' position of the sugar.

[0197] In yet another alternative embodiment, the capping group is present on the 2' or 4' carbon of the pentose sugar and may be of a size or structure sufficient to act as a barrier to the incorporation of additional nucleotides.

[0198] The use of blocking groups allows for control of polymerization, such as by stopping extension when a labeled nucleotide is incorporated. If the blocking effect is reversible, e.g., by way of non-limiting example, extension can be stopped at certain points by changing the chemical conditions or by removing the chemical barrier and then allowed to continue.

[0199] In a specific embodiment, connecting base (between dyestuff and nucleotide) and end-capping group both all exist and are independent parts.In a specific embodiment, connecting base and end-capping group both are cleavable under identical or substantially similar conditions.Therefore, deprotection and deblocking process may be more effective, because only need single treatment just can remove dye compound and blocking group both.But, in some embodiments, connecting base and end-capping group do not need to can crack under similar conditions, but can crack separately under different conditions.

[0200] The present disclosure also encompasses polynucleotides incorporating dye compounds. Such polynucleotides can be DNA or RNA composed of deoxyribonucleotides or ribonucleotides joined with phosphodiester bonds, respectively. Polynucleotides can include naturally occurring nucleotides combined with at least one modified nucleotide (e.g., labeled with a dye compound) as shown herein, non-naturally occurring (or modified) nucleotides or any combination thereof except the nucleotides of the labeling described herein. Polynucleotides according to the present disclosure can also include non-natural backbone bonds and / or non-nucleotide chemical modifications. It is also envisioned that a chimeric structure consisting of a mixture of ribonucleotides and deoxyribonucleotides comprising at least one labeled nucleotide.

[0201] Non-limiting exemplary labeled nucleotides as described herein include:

[0202]

[0203]

[0204] wherein L represents a linker and R represents a ribose or deoxyribose moiety as described above, or a ribose or deoxyribose moiety having the 5' position substituted with a monophosphate, diphosphate or triphosphate.

[0205] In some embodiments, non-limiting exemplary fluorescent dye conjugates are shown below:

[0206]

[0207]

[0208]

[0209] wherein PG represents a 3'OH capping group as described herein; p is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and k is 0, 1, 2, 3, 4, or 5. In one embodiment, -O-PG is AOM. In another embodiment, -O-PG is -O-azidomethyl. In one embodiment, k is 5. In some further embodiments, p is 1, 2, or 3; and k is 5. Refers to the point of attachment of the dye to the cleavable linker as a result of a reaction between an amino group of the linker moiety and a carboxyl group of the dye. In any of the embodiments of the labeled nucleotides described herein, the nucleotide is a nucleotide triphosphate.

[0210] Other aspects of the present disclosure relate to oligonucleotides comprising nucleotides of labels as described herein. In some embodiments, the oligonucleotides are hybridized with at least a portion of a target polynucleotide. In some embodiments, the target polynucleotide is fixed on a solid support. In some other embodiments, the solid support comprises an array of multiple fixed target polynucleotides. In other embodiments, the solid support comprises a patterned flow cell. In other embodiments, the patterned flow cell is manufactured on a CMOS chip. In other embodiments, the patterned flow cell comprises a plurality of nanopores. In other other embodiments, a plurality of nanopores are directly aligned on each CMOS photodiode (pixel).

[0211] Reagent test kit

[0212] Provided herein is a kit comprising a first nucleotide labeled with a chromene and quinoline compound (i.e., a first label) of the present disclosure. In some embodiments, the kit also includes a second labeled nucleotide, which is labeled with a second compound (i.e., a second label), which is different from the chromene and quinoline in the nucleotide of the first label. In some embodiments, a single excitation source can be used to excite the nucleotide of the first label and the nucleotide of the second label, and the single excitation source can be a first light source with a first excitation wavelength. For example, the excitation bands of the first label and the second label can overlap at least partially, so that the excitation in the spectral overlap region causes the two labels to emit fluorescence. In some other embodiments, the kit can include a third nucleotide, wherein the third nucleotide is labeled with a third compound (i.e., a third label) different from the first label and the second label. In some such embodiments, the nucleotide of the first label and the nucleotide of the third label can be excited using a second excitation source, and the second excitation source can be a second light source with a second excitation wavelength different from the first excitation wavelength. For example, the excitation bands of the first label and the third label can overlap at least partially, so that the excitation in the spectral overlap region causes the two labels to emit fluorescence. In some other embodiments, the kit can also include a fourth nucleotide. In some such embodiments, the fourth nucleotide is unlabeled (dark). In other embodiments, compared with the first nucleotide, the second nucleotide and the third nucleotide, the fourth nucleotide is labeled with different compounds, and each label has different absorbance maxima that can be distinguished from other labels. In still other embodiments, the fourth nucleotide is unlabeled. In some embodiments, the first excitation light source has a wavelength of about 500nm to about 550nm, about 510nm to about 540nm or about 520nm to about 530nm (e.g., 520nm). The second light source has an excitation wavelength of about 400nm to about 480nm, about 420nm to about 470nm or 450nm to about 460nm (e.g., 450nm). In an alternative embodiment, the first light source has an excitation wavelength of about 400nm to about 480nm, about 420nm to about 470nm or 450nm to about 460nm (e.g., 450nm). The second excitation light source has a wavelength of about 500nm to about 550nm, about 510nm to about 540nm or about 520nm to about 530nm (e.g., 520nm). The second light source has an excitation wavelength of about 400 nm to about 480 nm, about 420 nm to about 470 nm, or 450 nm to about 460 nm (e.g., 450 nm). In other embodiments, each of the first label, the second label, and the third label has an emission spectrum that can be collected in a single emission collection filter or channel.

[0213] In some embodiments, the kit may include four kinds of labeled nucleotides (A, C, G and T or U), wherein the first nucleotide in the four kinds of nucleotides is labeled with a compound as disclosed herein. In this kit, each of the four kinds of nucleotides can be labeled with a compound identical or different from the labeling on the other three kinds of nucleotides. Alternatively, the first nucleotide in the four kinds of nucleotides is a labeled nucleotide described herein, the second nucleotide in the four kinds of nucleotides carries a second labeling, the third nucleotide carries a third labeling, and the fourth nucleotide is unlabeled (dark). As another example, the first nucleotide in the four kinds of nucleotides is a labeled nucleotide described herein, the second nucleotide in the four kinds of nucleotides carries a second labeling, the third nucleotide carries a mixture of two labels, and the fourth nucleotide is unlabeled (dark). Therefore, one or more of the labeled compounds can have different absorbance maxima and / or emission maxima, so that the compound can be distinguished from other compounds. For example, each compound can have different absorbance maxima and / or emission maxima, so that each of these compounds can be distinguished from other three compounds (or if the fourth nucleotide is unlabeled, two compounds) in the spectrum. Should be understood that the part except maximum value in absorption spectrum and / or emission spectrum can be different, and these differences can be utilized to distinguish chemical compounds.This test kit can be such: that is, two or more compounds in these chemical compounds have different absorbance maxima.Chrome ene and quinoline dye disclosed herein absorbs the light in the zone lower than 500nm usually.For example, these chrome ene and quinoline dyes can have the absorption wavelength of about 450nm to about 530nm, about 460nm to about 520nm, about 475nm to about 510nm or about 490nm to about 500nm.

[0214] The compounds, nucleotides or kits shown herein can be used to detect, measure or identify biological systems (including, for example, processes or components thereof). Exemplary techniques that can employ the compounds, nucleotides or kits include sequencing, expression analysis, hybridization analysis, genetic analysis, RNA analysis, cell assays (e.g., cell binding or cell function analysis) or protein assays (e.g., protein binding assays or protein activity assays). The use can be on an automated instrument (such as an automated sequencing instrument) for performing a particular technique. A sequencing instrument can include two light sources operating at different wavelengths.

[0215] In a specific embodiment, the nucleotides of the labeling described herein can be combined with unlabeled or natural nucleotides or any combination thereof. The combination of nucleotides can be provided as an independent individual component (e.g., one nucleotide type per container or tube) or as a nucleotide mixture (e.g., two or more nucleotides mixed in the same container or tube).

[0216] In the case where the test kit comprises a variety, particularly two or three or more particularly four nucleotides, different nucleotides can be marked with different dye compounds, or one can be dark, without dye compounds. In the case where different nucleotides are marked with different dye compounds, a feature of the test kit is that the dye compound is a spectrally distinguishable fluorescent dye. As used herein, the term "spectrally distinguishable fluorescent dye" refers to a fluorescent dye that emits fluorescent energy at a wavelength that can be distinguished by a fluorescence detection device (e.g., a commercial capillary-based DNA sequencing platform) when there are two or more such dyes in a sample. When two nucleotides marked with fluorescent dye compounds are provided in a test kit form, some embodiments are characterized in that the spectrally distinguishable fluorescent dye can be excited with the same wavelength, for example, by the same light source. When four nucleotides marked with fluorescent dye compounds are provided in a test kit form, some embodiments are characterized in that two fluorescent dyes in the spectrally distinguishable fluorescent dye can be excited with a wavelength, and two other spectrally distinguishable dyes can be excited with another wavelength. The specific excitation wavelength of the dye is between 450 nm and 460 nm, between 490 nm and 500 nm, or 520 nm or above (eg, 532 nm).

[0217] In some embodiments, the test kit comprises the first nucleotide with the disclosed chromene and quinoline dye mark and the second nucleotide with the second dye mark, wherein the dye has at least 10nm, specifically 20nm to 50nm or 30nm to 40nm absorbance maximum difference.More specifically, the first mark can have a Stokes shift higher than 50nm, higher than 60nm, higher than 70nm or higher than 80nm.The second mark can have an approximately 80nm, higher than 90nm or higher than 100nm Stokes shift (wherein " Stokes shift " is the distance between the peak absorption wavelength and the peak emission wavelength).In addition, the first mark can have an absorption maximum of approximately 460nm to approximately 520nm, approximately 475nm to approximately 510nm or approximately 490nm to approximately 500nm.The second mark can have an absorption maximum of approximately 400nm to approximately 470nm or approximately 450nm to approximately 460nm.In other embodiments, the test kit can also the nucleotide of the 3rd mark, wherein the 3rd mark has an absorption maximum higher than 520nm. The 3rd mark can have the Stokes shift higher than 20nm, higher than 30nm or higher than 40nm, or the Stokes shift between 20nm-40nm.Kit can also include the 4th unlabeled Nucleotide.In other embodiments, each mark in the first mark, the second mark and the 3rd mark has the emission maximum greater than 540nm, greater than 550nm, greater than 560nm, greater than 570nm, greater than 580nm, greater than 590nm or greater than 600nm.In some embodiments, can detect or collect the emission spectrum of the first mark, the second mark and the 3rd mark in single emission collection channel or optical filter (for example, from about 580nm to the collection area of ​​about 700nm).

[0218] In an alternative embodiment, the kit of the present disclosure can include nucleotides in which the same base is labeled with two different compounds. The first nucleotide can be labeled with a compound of the present disclosure. The second nucleotide can be labeled with a different compound on the spectrum, such as a "green" dye that absorbs less than 600nm. The third nucleotide can be labeled with a mixture of a compound of the present disclosure and a different compound on the spectrum, and the fourth nucleotide can be "dark" and does not contain a mark. Therefore, simply put, nucleotides 1 to 4 can be labeled with "blue", "green", "blue / green" and dark. In order to further simplify the instrument, four types of nucleotides can be labeled with two dyes excited by a single light source, and therefore the marks of nucleotides 1 to 4 can be "blue 1", "blue 2", "blue 1 / blue 2" and dark.

[0219] Although the kit is described herein as having different nucleotides labeled with different dye compounds, it should be understood that the kit can include 2, 3, 4 or more different nucleotides with the same dye compound.

[0220] In addition to the labeled nucleotides, the test kit can also include at least one additional component together. The additional component can be one or more components in the components identified in the method shown herein or in the Examples section below. Some non-limiting examples of components that can be incorporated into the test kit of the present disclosure are shown below. In some embodiments, the test kit also includes DNA polymerase (such as mutant DNA polymerase) and one or more buffer compositions. A buffer composition can include an antioxidant, such as ascorbic acid or sodium ascorbate, which can be used to protect the dye compound from light damage during detection. Other buffer compositions can include reagents that can be used to crack 3' blocking groups and / or cleavable linking groups. For example, a water-soluble phosphine or water-soluble transition metal catalyst formed by a transition metal and at least a portion of a water-soluble ligand (such as a palladium complex). The various components of the test kit can be provided in a concentrated form diluted before use. In such embodiments, a suitable dilution buffer can also be included. Similarly, one or more components in the components identified in the method shown herein can be included in the test kit of the present disclosure. In any embodiment of the nucleotides or labeled nucleotides described herein, the nucleotides include 3' hydroxyl blocking groups.

[0221] Sequencing methods

[0222] Nucleotides comprising dye compounds according to the present disclosure can be used in any analytical method, such as methods including detecting fluorescent labels attached to such nucleotides, whether used by themselves, or incorporated into or associated with larger molecular structures or conjugates. In this context, the term "incorporated into a polynucleotide" can mean that the 5' phosphate is joined to the 3' hydroxyl group of the second nucleotide with a phosphodiester bond, and the second nucleotide itself can form a part of a longer polynucleotide chain. The 3' end of the nucleotide shown herein may or may not be joined to the 5' phosphate of another nucleotide with a phosphodiester bond. Therefore, in a non-limiting embodiment, the present disclosure provides a method for detecting the labeled nucleotides incorporated into a polynucleotide, the method comprising: (a) incorporating at least one labeled nucleotide of the present disclosure into a polynucleotide, and (b) determining the identity of the nucleotide incorporated into the polynucleotide by detecting a fluorescent signal from a dye compound attached to the nucleotide.

[0223] The method may include: a synthesis step (a), in which one or more labeled nucleotides according to the present disclosure are incorporated into a polynucleotide; and a detection step (b), in which the nucleotides are detected by detecting or quantitatively measuring the fluorescence of the one or more labeled nucleotides incorporated into the polynucleotide.

[0224] Some embodiments of the present application relate to a method for determining the sequence of a target polynucleotide (e.g., a single-stranded target polynucleotide), the method comprising: (a) contacting a primer polynucleotide with one or more labeled nucleotides (such as nucleoside triphosphates A, G, C, and T), wherein at least one of the labeled nucleotides is a labeled nucleotide described herein, and wherein the primer polynucleotide is complementary to at least a portion of the target polynucleotide; (b) incorporating the labeled nucleotide into the primer polynucleotide; and (c) performing one or more fluorescence measurements to determine the identity of the incorporated nucleotide. In some such embodiments, a primer polynucleotide / target polynucleotide complex is formed by contacting a target polynucleotide with a primer polynucleotide complementary to at least a portion of the target polynucleotide. In some embodiments, the method further comprises (d) removing the labeling portion and the 3' hydroxyl blocking group from the nucleotides incorporated into the primer polynucleotide. In some additional embodiments, the method may also comprise (e) washing away the removed labeling portion and the 3' blocking group from the primer polynucleotide chain. In some embodiments, repeat step (a) to step (d) or step (a) to step (e), until determining the sequence of at least a portion of the target polynucleotide chain. In some cases, step (a) to (d) or step (a) to (e) repeats at least 30,40,50,60,70,80,90,100,110,120,130,140,150,160,170,180,190,200,250 or 300 cycles. In some embodiments, remove the labeling part and 3' blocking group from the nucleotides incorporated into the primer polynucleotide chain in a single chemical reaction. In some other embodiments, the method is performed on an automated sequencing instrument, and wherein the automated sequencing instrument is included in two light sources operating at different wavelengths. In some embodiments, sequence determination is performed after completing the repeated cycles of sequencing steps as described herein.

[0225] Some embodiments of the present disclosure relate to a method for determining the sequence of a target polynucleotide (e.g., a single-stranded target polynucleotide), the method comprising: (a) contacting a primer polynucleotide with an incorporation mixture comprising one or more nucleotide conjugates of four different types of nucleotide conjugates, wherein the first type of nucleotide conjugate comprises a first label, the second type of nucleotide conjugate comprises a second label, and the third type of nucleotide conjugate comprises a third label, wherein each of the first label, the second label, and the third label is spectrally different from each other, and wherein the primer polynucleotide is complementary to at least a portion of the target polynucleotide; (b) incorporating a nucleotide conjugate from the mixture into the primer polynucleotide to produce an extended primer polynucleotide; (c) performing a first imaging event using a first excitation light source and detecting a first emission signal from the extended polynucleotide; and (d) performing a second imaging event using a second excitation light source and detecting a second emission signal from the extended polynucleotide; wherein the first excitation light source and the second excitation light source have different wavelengths; and wherein the first emission signal and the second emission signal are detected or collected in a single emission detection channel. In some embodiments, the chromene-quinoline dye described herein can be used as any of the first label, the second label, or the third label described in the method. In some embodiments, the method does not include chemical modification of any nucleotide conjugate in the mixture after the first imaging event and before the second imaging event. In some other embodiments, the incorporation mixture also includes a fourth type of nucleotides, wherein the fourth type of nucleotides are unlabeled or labeled with a fluorescent moiety that does not emit a signal from the first imaging event or the second imaging event. In this sequencing method, the identity of each incorporated nucleotide conjugate is determined based on the detection mode of the first imaging event and the second imaging event. For example, the incorporation of the first type of nucleotide conjugate is determined by the signal state in the first imaging event and the dark state in the second imaging event. The incorporation of the second type of nucleotide conjugate is determined by the dark state in the first imaging event and the signal state in the second imaging event. The incorporation of the third type of nucleotide conjugate is determined by the signal state in both the first imaging event and the second imaging event. The incorporation of the fourth type of nucleotide conjugate is determined by the dark state in both the first imaging event and the second imaging event. In other embodiments, steps (a) to (d) are performed in a repeated cycle (e.g., at least 30, 50, 100, 150, 200, 250, 300, 400, or 500 times), and the method further comprises sequentially determining the sequence of at least a portion of the single-stranded target polynucleotide based on the identity of each sequentially incorporated nucleotide conjugate. In some embodiments, the first excitation light source has a shorter wavelength than the second excitation light source. In some such embodiments, the first excitation light source has a wavelength of about 400 nm to about 480 nm, about 420 nm to about 470 nm, or about 450 nm to about 460 nm (i.e., "blue light").In one embodiment, the first excitation light source has a wavelength of about 450nm. The second excitation light source has a wavelength of about 500nm to about 550nm, about 510nm to about 540nm, or about 520nm to about 530nm (i.e., "green light"). In one embodiment, the second excitation light source has a wavelength of about 520nm. In other embodiments, the first excitation light source has a longer wavelength than the second excitation light source. In some such embodiments, the first excitation light source has a wavelength of about 500nm to about 550nm, about 510nm to about 540nm, or about 520nm to about 530nm (i.e., "green light"). In one embodiment, the second excitation light source has a wavelength of about 520nm. The second excitation light source has a wavelength of about 400nm to about 480nm, about 420nm to about 470nm, or about 450nm to about 460nm (i.e., "blue light"). In one embodiment, the second excitation light source has a wavelength of about 450nm.

[0226] In some embodiments, at least one nucleotide is incorporated into a polynucleotide (such as a single-stranded primer polynucleotide described herein) by the action of a polymerase during a synthesis step. However, other methods of joining nucleotides to polynucleotides can be used, such as chemical oligonucleotide synthesis or connecting labeled oligonucleotides to unlabeled oligonucleotides. Therefore, when the term "incorporation" is used with respect to nucleotides and polynucleotides, polynucleotide synthesis by chemical methods as well as enzymatic methods can be encompassed.

[0227] In a particular embodiment, a synthesis step is performed and the synthesis step may optionally include incubating the template or target polynucleotide chain with a reaction mixture comprising fluorescently labeled nucleotides of the present disclosure. A polymerase may also be provided under conditions that allow the formation of a phosphodiester bond between a free 3' hydroxyl group on the polynucleotide chain annealed to the template or target polynucleotide chain and a 5' phosphate group on the labeled nucleotide. Thus, the synthesis step may include directing the formation of a polynucleotide chain by complementary base pairing of nucleotides with the template / target chain.

[0228] In all embodiments of the method, the detection step can be performed when the polynucleotide chain into which the nucleotides of the mark are incorporated is annealed to the template / target chain, or after a denaturation step in which the two chains are separated. Additional steps, such as a chemical reaction step or an enzymatic reaction step, or a purification step may be included between the synthesis step and the detection step. Specifically, the polynucleotide chain into which the nucleotides of the mark are incorporated can be separated or purified, and then further processed or used for subsequent analysis. By way of example, the polynucleotide chain into which the nucleotides of the mark as described herein are incorporated in the synthesis step can be used as a probe or primer for labeling subsequently. In other embodiments, the product of the synthesis step shown herein can be subjected to further reaction steps, and if desired, the products of these subsequent steps are purified or separated.

[0229] Suitable conditions for the synthesis step will be well known to those familiar with standard molecular biology techniques. In one embodiment, the synthesis step can be similar to a standard primer extension reaction, which uses nucleotide precursors (including the nucleotides of labels as described herein) to form a polynucleotide chain (primer polynucleotide chain) complementary to the template / target chain in the presence of a suitable polymerase. In other embodiments, the synthesis step itself can form a part of the amplification reaction of the double-stranded amplification product of the mark, and the double-stranded amplification product of the mark is composed of the annealing complementary chain derived from the replication of the primer polynucleotide chain and the template polynucleotide chain. Other exemplary synthesis steps include nick translation, strand displacement polymerization, random DNA labeling, etc. The particularly useful polymerase for the synthesis step is a polymerase that can catalyze the incorporation of the nucleotides of the labels shown in this article. A variety of naturally occurring or mutated / modified polymerases can be used. By way of example, a thermostable polymerase can be used for the synthesis reaction performed using thermal cycling conditions, and a thermostable polymerase may not be desired by an isothermal primer extension reaction. Suitable thermostable polymerases capable of incorporating labeled nucleotides according to the present disclosure include those described in WO 2005 / 024010 or WO06120433, each of which is incorporated herein by reference. In synthesis reactions conducted at lower temperatures such as 37° C., the polymerase need not be a thermostable polymerase, and thus the choice of polymerase will depend on many factors, such as reaction temperature, pH, strand displacement activity, etc.

[0230] In specific non-limiting embodiments, the present disclosure encompasses methods for nucleic acid sequencing, resequencing, whole genome sequencing, single nucleotide polymorphism scoring, and any other application involving the detection of modified nucleotides or nucleosides labeled with the dyes set forth herein when incorporated into polynucleotides.

[0231] Specific embodiments of the present disclosure provide the purposes of the nucleotides comprising the labeling of the dye moiety according to the present disclosure in the sequencing reaction while synthesizing the polynucleotides.Synthesis sequencing generally involves using polymerase or ligase to sequentially add one or more nucleotides or oligonucleotides to the growing polynucleotide chain in 5' to 3' direction, so as to form an extended polynucleotide chain complementary to the template / target nucleic acid to be sequenced. The identity of the base present in the one or more added nucleotides can be determined in detection or "imaging" steps. The identity of the added base can be measured after each nucleotide incorporation step. Conventional Watson-Crick base pairing rules can then be used to infer the sequence of the template. Using the nucleotides labeled with the dyes shown herein to determine the identity of a single base may be useful, for example, in the scoring of a single nucleotide polymorphism, and such single base extension reactions are within the scope of the present disclosure.

[0232] In one embodiment of the present disclosure, the sequence of the template / target polynucleotide is determined by detecting the incorporation of one or more nucleotides into a nascent chain complementary to the template polynucleotide to be sequenced by detecting a fluorescent label attached to the incorporated nucleotides. The sequencing of the template polynucleotide can be initiated with a suitable primer (or prepared as a hairpin construct, which will include a primer as part of the hairpin), and the nascent chain is extended in a one-by-one manner by adding nucleotides to the 3' end of the primer in a polymerase-catalyzed reaction.

[0233] In a specific embodiment, each of the different nucleotide triphosphates (A, T, G and C) can be labeled with a unique fluorophore, and a blocking group is also included at the 3' position to prevent uncontrolled polymerization. Alternatively, one of the four nucleotides can be unlabeled (dark). Polymerase incorporates nucleotides into a nascent chain complementary to the template / target polynucleotide, and the blocking group prevents further incorporation of nucleotides. Any unincorporated nucleotides can be washed away, and the fluorescent signal from the nucleotides of each incorporation can be optically "read" by a suitable device (such as a charge-coupled device using a light source to excite and a suitable emission filter). Then 3' blocking groups and fluorescent dye compounds can be removed (simultaneously or sequentially) to expose the nascent chain for further incorporation of nucleotides. Typically, the identity of the nucleotides incorporated will be determined after each incorporation step, but this is not strictly necessary. Similarly, U.S. Patent No. 5,302,509 (which is incorporated herein by reference) discloses a method for sequencing a polynucleotide fixed on a solid support.

[0234] As illustrated above, the method utilizes the presence of DNA polymerase to incorporate fluorescently labeled 3'-enclosed nucleotides A, G, C and T into a growing chain complementary to a fixed polynucleotide. Polymerase incorporates bases complementary to the target polynucleotide, but is prevented from further addition by 3'-enclosed groups. The label of the nucleotides incorporated can then be determined, and the enclosed groups are removed by chemical cleavage to allow further polymerization to occur. The nucleic acid template to be sequenced in the synthesis sequencing reaction can be any polynucleotide that is desired to be sequenced. The nucleic acid template for sequencing reaction will generally include a double-stranded region with a free 3' hydroxyl group, which serves as a primer or starting point for adding additional nucleotides in the sequencing reaction. The region of the template to be sequenced will dangle the free 3' hydroxyl group on the complementary chain. The overhanging region of the template to be sequenced can be single-stranded, but can also be double-stranded, provided that there is a "nick" on the chain complementary to the template chain to be sequenced, to provide a free 3' OH group for initiating sequencing reactions. In such embodiments, sequencing can be performed by strand displacement. In certain embodiments, primers with free 3' hydroxyl groups can be added as separate components (e.g., short oligonucleotides) hybridized with the single-stranded region of template to be sequenced. Alternatively, primers to be sequenced and template strands can each form a part of a partial self-complementary nucleic acid chain that can form an intramolecular duplex (such as a hairpin loop structure). Hairpin polynucleotides and methods that can be attached to solid supports thereof are disclosed in PCT Publication No. WO0157248 and WO2005 / 047301, and each of these disclosures is incorporated herein by reference. Nucleotide can be continuously added to the growth primer, resulting in a synthetic polynucleotide chain in the 5' to 3' direction. The properties of the bases added can be determined, particularly but not necessarily after each addition of nucleotides, thereby providing the sequence information of nucleic acid templates. Therefore, by forming a phosphodiester bond with the 5' phosphate group of nucleotides and nucleotides being joined to the free 3' hydroxyl group of nucleic acid chain, the nucleotides are incorporated into the nucleic acid chain (or polynucleotides).

[0235] The nucleic acid template to be sequenced can be DNA or RNA, or even a hybrid molecule composed of deoxynucleotides and ribonucleotides. The nucleic acid template can contain naturally occurring and / or non-naturally occurring nucleotides and natural or non-natural backbone bonds, provided that these do not prevent replication of the template in the sequencing reaction.

[0236] In certain embodiments, the nucleic acid template to be sequenced can be attached to a solid support via any suitable connection method known in the art (e.g., via covalent attachment). In certain embodiments, the template polynucleotide can be directly attached to a solid support (e.g., a silica-based support). However, in other embodiments of the present disclosure, the surface of the solid support can be modified in some way to allow direct covalent attachment of the template polynucleotide, or the template polynucleotide can be fixed by a hydrogel or polyelectrolyte multilayer that can itself be non-covalently attached to the solid support.

[0237] In some embodiments, the polynucleotides are directly attached to a carrier (e.g., a silica-based carrier, such as those disclosed in WO00 / 06770 (incorporated herein by reference)), wherein the polynucleotides are fixed to a glass carrier by reaction between an epoxy side group on the glass and an internal amino group on the polynucleotides. In addition, polynucleotides can be attached to a solid carrier by reaction of a sulfonyl nucleophilic substance with a solid carrier, for example, as described in WO2005 / 047301 (incorporated herein by reference). Other additional examples of template polynucleotides supported by solids are template polynucleotides attached to a hydrogel loaded on silica or other solid carriers, for example, as described in WO00 / 31148, WO01 / 01143, WO02 / 12566, WO03 / 014392, U.S. Patent No. 6,465,178 and WO00 / 53812, each of which is incorporated herein by reference.

[0238] The specific surface on which the template polynucleotide can be fixed is a polyacrylamide hydrogel. Polyacrylamide hydrogels are described in the references cited above and WO2005 / 065814, which is incorporated herein by reference. Specific hydrogels that can be used include those described in WO2005 / 065814 and U.S. Publication 2014 / 0079923. In one embodiment, the hydrogel is PAZAM (poly (N- (5-azidoacetamidopentyl) acrylamide-co-acrylamide)).

[0239] The DNA template molecules can be attached to beads or microparticles, for example, as described in U.S. Pat. No. 6,172,218 (which is incorporated herein by reference). Attachment to beads or microparticles can be used for sequencing applications. Bead libraries can be prepared, wherein each bead contains a different DNA sequence. Exemplary libraries and methods for their generation are described in Nature, 437, 376-380 (2005); Science, 309, 5741, 1728-1732 (2005), each of which is incorporated herein by reference. It is within the scope of the present disclosure to sequence arrays of such beads using the nucleotides set forth herein.

[0240] The template to be sequenced can form part of an "array" on a solid support, in which case the array can take any convenient form. Therefore, the method of the present disclosure is applicable to all types of high-density arrays, including single-molecule arrays, clustered arrays, and bead arrays. Nucleotides labeled with dye compounds of the present disclosure can be used to sequence templates on substantially any type of array (including but not limited to those formed by fixing nucleic acid molecules on a solid support).

[0241] However, nucleotides labeled with dye compounds of the present disclosure are particularly advantageous in the context of sequencing clustered arrays. In clustered arrays, different regions on the array (commonly referred to as sites or features) include multiple polynucleotide template molecules. Generally speaking, the multiple polynucleotide molecules can not be distinguished individually by optical means, but are detected as a whole. Depending on the formation mode of the array, each site on the array can include multiple copies of a single polynucleotide molecule (for example, the site is homogeneous for specific single-stranded nucleic acid species or double-stranded nucleic acid species) or even a small amount of multiple copies of different polynucleotide molecules (for example, multiple copies of two different nucleic acid species). The clustered array of nucleic acid molecules can be produced using technology known in the art. By way of example, WO 98 / 44151 and WO00 / 18957 (each of these patents is incorporated herein by reference) describe a method for amplifying nucleic acids, wherein template and amplification product are both kept fixed on a solid support, so as to form an array consisting of a cluster or " colony" of fixed nucleic acid molecules. Nucleic acid molecules present on clustered arrays prepared according to these methods are suitable templates for sequencing using nucleotides labeled with the dye compounds of the present disclosure.

[0242] Nucleotides labeled with dye compounds of the present disclosure can also be used to sequence the templates on single molecule arrays. As used herein, the term "single molecule array" or "SMA" refers to a polynucleotide molecule population distributed (or arranged) on a solid support, wherein the spacing between any single polynucleotide and all other polynucleotides of the molecule population makes it possible to distinguish the single polynucleotide molecules individually. Therefore, in some embodiments, the target nucleic acid molecules fixed to the surface of the solid support can be distinguished by optical means. This means that one or more different signals (each signal represents a polynucleotide) will appear in the distinguishable region of the specific imaging device used.

[0243] Single molecule detection can be achieved, wherein the spacing between adjacent polynucleotide molecules on the array is at least 100 nm, more specifically at least 250 nm, more specifically at least 300 nm, and even more specifically at least 350 nm. Therefore, each molecule can be individually resolved and detected as a single molecule fluorescent spot, and the fluorescence from the single molecule fluorescent spot also exhibits single-step photobleaching.

[0244] The terms "individually resolved" and "individually resolved" are used herein to specify that, when visualized, it is possible to distinguish a molecule on an array from its adjacent molecules. The spacing between the individual molecules on the array will be determined in part by the specific techniques used to resolve the individual molecules. The general characteristics of single molecule arrays will be understood by reference to published applications WO 00 / 06770 and WO 01 / 57248, each of which is incorporated herein by reference. Although one use of the labeled nucleotides of the present disclosure is for synthetic sequencing reactions, the effectiveness of such nucleotides is not limited to such methods. In fact, the labeled nucleotides described herein can be advantageously used in any sequencing method that requires detection of fluorescent labels attached to nucleotides incorporated into the polynucleotides.

[0245] Specifically, nucleotides labeled with dye compounds of the present disclosure can be used in automated fluorescent sequencing protocols, especially fluorescent dye-terminator cycle sequencing based on the chain termination sequencing method of Sanger and colleagues. Such methods typically use enzymes and cycle sequencing to incorporate fluorescently labeled dideoxynucleotides into primer extension sequencing reactions. The so-called Sanger sequencing method and related protocols (Sanger-type) utilize randomized chain termination of labeled dideoxynucleotides.

[0246] Thus, the present disclosure also encompasses nucleotides labeled with dye compounds that are dideoxynucleotides lacking hydroxyl groups at both the 3' and 2' positions, such modified dideoxynucleotides being suitable for use in Sanger-type sequencing methods and the like.

[0247] It will be appreciated that nucleotides labeled with dye compounds of the present disclosure incorporating 3' blocking groups may also be used in Sanger methods and related protocols, since the same effect as that achieved by using dideoxy nucleotides may be achieved by using nucleotides with 3'OH blocking groups: both prevent incorporation of subsequent nucleotides. In cases where nucleotides according to the present disclosure and with 3' blocking groups are to be used in Sanger-type sequencing methods, it will be appreciated that the dye compound or detectable label attached to the nucleotide need not be attached via a cleavable linker, since in each case of incorporating a labeled nucleotide of the present disclosure; no subsequent incorporation of a nucleotide is required, and therefore no removal of the label from the nucleotide is required.

[0248] Alternatively, unlabeled nucleotides and affinity reagents containing fluorescent dyes described herein can also be used to carry out sequencing methods described herein. For example, in the incorporation mixture of step (a), one type, two types, three types or each type of four different types of nucleotides (e.g., dATP, dCTP, dGTP and dTTP or dUTP) can be unlabeled. Each type of nucleotide (e.g., dNTP) in the four types of nucleotides has a 3' hydroxyl blocking group to ensure that only a single base can be added to the 3' end of the primer polynucleotide by a polymerase. After incorporating unlabeled nucleotides in step (b), the remaining unincorporated nucleotides are washed away. Then an affinity reagent is introduced, which specifically recognizes and binds to the incorporated dNTP to provide an extension product containing the label of the incorporated dNTP. The use of unlabeled nucleotides and affinity reagents in synthetic sequencing has been disclosed in WO 2018 / 129214 and WO 2020 / 097607. The sequencing method of the modification of the present disclosure using unlabeled nucleotides may include the following steps:

[0249] (a') contacting a primer polynucleotide / target polynucleotide complex with one or more unlabeled nucleotides (e.g., dATP, dCTP, dGTP, and dTTP or dUTP), wherein the primer polynucleotide is complementary to at least a portion of the target polynucleotide;

[0250] (b') incorporating nucleotides into the primer polynucleotide to produce an extended primer polynucleotide;

[0251] (c') contacting the extended primer polynucleotide with a set of affinity reagents under conditions where one affinity reagent specifically binds to the incorporated unlabeled nucleotide to provide a labeled extended primer polynucleotide / target polynucleotide complex;

[0252] (d') performing one or more fluorescence measurements on the labeled extended primer polynucleotide / target polynucleotide complex to determine the identity of the incorporated nucleotide.

[0253] In some embodiments of the sequencing method of the modification described herein, each nucleotide in the unlabeled nucleotides incorporated into the mixture contains a 3' hydroxyl blocking group. In other embodiments, the 3' hydroxyl blocking group of the incorporated nucleotide is removed before the next incorporation cycle. In other other embodiments, the method also includes removing the affinity reagent from the incorporated nucleotide. In some other embodiments, the 3' hydroxyl blocking group and the affinity reagent are removed in the same reaction. In some embodiments, the affinity reagent group may include a first affinity reagent that specifically binds to the first type of nucleotide, a second affinity reagent that specifically binds to the second type of nucleotide, and a third affinity reagent that specifically binds to the third type of nucleotide. In some other embodiments, each of the first affinity reagent, the second affinity reagent, and the third affinity reagent includes a spectrally distinguishable detectable label. In some embodiments, the affinity reagent may include a protein tag, an antibody (including but not limited to a binding fragment of an antibody, a single-chain antibody, a bispecific antibody, etc.), an aptamer, a knotting element, an affimer, or any other known reagent that binds to the incorporated nucleotide with suitable specificity and affinity. In one embodiment, at least one affinity reagent is an antibody or a protein tag. In another embodiment, at least one of the first type of affinity reagent, the second type of affinity reagent, and the third type of affinity reagent is an antibody or protein tag comprising one or more detectable labels (e.g., multiple copies of the same detectable label), wherein the detectable label is or includes a chromenoquinoline dye moiety described herein.

[0254] Example

[0255] Additional embodiments are disclosed in more detail in the following examples, which are not intended to limit the scope of the claims in any way.

[0256] Example 1. Synthesis of chromenoquinoline dyes

[0257] Synthesis of Chromenoquinoline Dye Intermediates

[0258]

[0259] Tert-butyl gamma-(7-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl)butanoate (1) (3.94 g, 13.5 mmol) was co-evaporated with anhydrous N,N'-dimethylformamide (DMF) (3 x 10 mL). Phosphorus oxychloride (1.9 mL, 20 mmol) was added to 30 mL of anhydrous DMF at 0 °C. After 15 minutes, the solution turned light pink and a solution of 1 in 10 mL of DMF was added. The reaction was stirred for 3 hours at RT and then quenched with 10 mL of saturated aqueous NaHCO3. After 5 minutes, the volatiles were removed under reduced pressure, leaving a dark green oil. 300 mL of saturated aqueous NaHCO3 was added, and the solution was extracted with 5 x 200 mL of ethyl acetate. The collected organic phases were dried over MgSO4, filtered and evaporated or dried under reduced pressure. The residue was purified by flash chromatography on silica gel to give compound 2. Yield: 3.656 g, green oil (11.4 mmol, 84%). LC-MS (ES and CI): (positive ion) m / z 320 (M+H + ); (negative ion) m / z 318 (MH + ).

[0260] Tert-butyl γ-(6-formyl-7-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl)butanoate (2) (2.46 g, 7.72 mmol) was dissolved in anhydrous DMF, followed by the addition of K2CO3 (2.13 g, 15.4 mmol), tetrabutylammonium iodide (258 mg, 0.70 mmol) and propargyl bromide (80 wt % in toluene, 1.28 mL, 11.6 mmol). The reaction system was stirred overnight at RT, then quenched with 150 mL of water and then extracted with 200 mL of ethyl acetate. The aqueous phase was separated and extracted with 2×100 mL of ethyl acetate. The combined organic phases were then extracted again with 2×100 mL of water. The organic phases were dried over MgSO4, filtered and evaporated or dried under reduced pressure. The residue was purified by flash chromatography on silica gel to give compound 3. Yield: 2.01 g, yellow solid (5.65 mmol, 73%). LC-MS (ESI): (positive ion) m / z 358 (M+H + ),380(M+Na + ).

[0261]

[0262] Compound 5 was synthesized from tert-butyl γ-(1-dimethyl-3-methyl-6-formyl-7-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl)butanoate (4) according to the method described for compound 3 as an off-white solid. Yield: 351 mg (0.86 mmol, 86%). LC-MS (ES and CI): (positive ion) m / z 400 (M+H+ ).

[0263]

[0264] Compound 7 was synthesized from 4-(diethylamino) salicylaldehyde (6) according to the method described for compound 3 as a light pink solid. Yield: 2.263 mg (9.97 mmol, 95%). LC-MS (ES and CI): (positive ion) m / z 232 (M+H + ).

[0265] General Synthesis of Chromenoquinoline Dyes

[0266]

[0267] Under N2, substituted 4-amino-2-propargyloxy-benzaldehyde (0.336mmol) and substituted aniline (0.37mmol) were dissolved in anhydrous DMF, then acetic acid (10 μL, 0.16mmol) was added and the solution was heated to 60°C for 1 hour. TLC (petroleum ether / ethyl acetate 1: 1) showed the formation of a yellow intermediate. Then, CuI (13mg, 0.067mmol) was added, and the reaction system was stirred at 60°C to 100°C until completion. The reaction system was diluted with 30mL ethyl acetate, filtered on a silica plug, and then purified by flash chromatography.

[0268] Compound 8a: Starting from intermediate 3 and p-aminoanisole, compound 8a was obtained with a yield of 31% as a yellow solid. LC-MS (ESI): (positive ion) m / z 461 (M+H + ).

[0269] Compound 8b: Starting from intermediate 3 and 4-methylaniline, compound 8b was obtained in 35% yield as a yellow solid (89 mg, 0.20 mmol). LC-MS (ESI): (positive ion) m / z 445 (M+H + ).

[0270] Compound 8c: Starting from intermediate 3 and 3,4-dimethylaniline, compound 8c was obtained as a 6:4 mixture of two regioisomers in 21% yield as a yellow solid (32 mg, 0.07 mmol). LC-MS (ESI): (positive ion) m / z 459 (M+H + ).

[0271] Compound 8d: Starting from intermediate 3 and 3,4-dimethoxyaniline, compound 8d was obtained with a yield of 48% as a yellow solid (68 mg, 0.138 mmol). LC-MS (ESI): (positive ion) m / z 491 (M+H+ ).

[0272] Compound 8e: Starting from intermediate 5 and p-anisidine, compound 8e was obtained with a yield of 40% as a yellow solid (76 mg, 0.151 mmol). LC-MS (ESI): (positive ion) m / z 503 (M+H + ).

[0273] Compound 8f: Starting from intermediate 7 and methyl (4-aminophenyl)acetate, compound 8f was obtained in 39% yield as a yellow solid (321 mg, 0.85 mmol). LC-MS (ESI): (positive ion) m / z 377 (M+H + ).

[0274] Compound 8g: Starting from intermediate 3 and 3,4-(methylenedioxy)aniline, compound 8g was obtained with a yield of 40% as a yellow solid (65 mg, 0.137 mmol). LC-MS (ESI): (positive ion) m / z 475 (M+H + ).

[0275] Compound 8h: Starting from intermediate 3 and 3,4,5-trimethoxyaniline, compound 8h was obtained with a yield of 35% as a yellow solid (65 mg, 0.117 mmol). LC-MS (ESI): (positive ion) m / z 521 (M+H + ).

[0276] Compound 8i: Starting from intermediate 3 and 5-amino-2,3-dihydrobenzofuran, compound 8i was obtained with a yield of 31% as a yellow solid (50 mg, 0.117 mmol). LC-MS (ESI): (positive ion) m / z 473 (M+H + ).

[0277]

[0278] Compound 8a (82 mg, 0.178 mmol) was dissolved in dry 1,4-dioxolane (2 mL) in a pressure tube. Iodomethane (0.5 mL, 8 mmol) was added and the reaction system was heated at 100 ° C. After 2 hours, it was cooled, the volatiles were removed under reduced pressure and the crude product was purified by flash column chromatography. The intermediate was then dissolved in dry DCM (1 mL), 0.5 mL of trifluoroacetic acid was added, and the reaction system was stirred at RT for 1.5 hours. The volatiles were then removed under reduced pressure and the crude product was purified by flash column chromatography to give compound I-1 as a red solid. Yield: 28 mg (0.067 mmol, 37%). 1H NMR (400MHz, MeOD): δ (ppm) 8.38 (s, 1H, Ar-CH), 7.64 (dd, J = 9.5, 2.9Hz, 1H, Ar-CH) ,7.57(s,1H,Ar-CH),7.51(d,J=2.9Hz,1H,Ar-CH),6.52(s,1H,Ar-CH),5.18(s,2H, CH2-O),4.46(s,3H,NCH3),3.99(s,3H,OCH3),3.55–3.45(m,4H,CH2-N),2.86(t,J= 6.2Hz, 2H, CH2-Ar), 2.41 (t, J = 6.9Hz, 2H, CH2-COO), 2.07–1.90 (m, 4H, CH2-CH2-N). LC-MS (ESI): (positive ion) m / z 419 (M+H + ).

[0279]

[0280] Compound 8b (89 mg, 0.20 mmol) was dissolved in dry 1,2-dichloroethane (2 mL) in a pressure tube. Methyl trifluoromethanesulfonate (0.45 mL, 4 mmol) and K2CO3 (138 mg, 1 mmol) were added, and the reaction system was heated at 110 ° C. After 18 hours, the reaction system was cooled, the volatiles were removed under reduced pressure and the crude product was purified by flash column chromatography. The intermediate was then dissolved in methanol (10 mL) and 0.5 mL of 4M NaOH aqueous solution was added. The reaction system was stirred at RT for 18 hours. Then, the solution was neutralized with 1N HCl, the volatiles were removed under reduced pressure, and the crude product was purified on a C18 column by preparative RP-HPLC to obtain compound I-2 as a red solid. Yield: 30 μmol (15%). 1 H NMR (400MHz, MeOD): δ (ppm) 8.33 (s, 1H, Ar-CH), 8.10 (d, J = 8.8Hz, 1H, Ar-CH), 7.92–7.8 4(m,2H,Ar-CH),7.57(s,1H,Ar-CH),6.53(s,1H,Ar-CH),5.16(s,2H,CH2-O),4.44(s,3 H, NCH3), 3.56–3.52 (m, 2H, CH2-N), 3.50–3.43 (m, 2H, CH2-N), 2.85 (t, J=6.2 Hz, 2H, CH2-Ar), 2.59 (s, 3H, CH3), 2.25 (t, J=7.2 Hz, 2H, CH2-COO), 2.06–1.89 (m, 4H, CH2-CH2-N). LC-MS (ESI): (positive ion) m / z 403 (M+H+ ).

[0281]

[0282] Compound 8c (30 mg, 0.065 mmol) was dissolved in dry 1,2-dichloroethane (1 mL) in a pressure tube. Methyl trifluoromethanesulfonate (1 mL) and diisopropylethylamine (0.5 mL) were added. After 1 h at RT, the mixture was diluted with DCM (20 mL) and the solution was extracted with 20 mL of saturated aqueous NaHCO3. The organic phase was dried over MgSO4, filtered and evaporated or dried under reduced pressure. The red residue was purified by flash column chromatography. The intermediate was then dissolved in methanol (10 mL) and 0.15 mL of 4M aqueous NaOH was added. The reaction system was stirred at RT for 18 h. The solution was then neutralized with 1N HCl (0.6 mL), the volatiles were removed under reduced pressure, and the crude product was purified by RP chromatography on a C18 column to give compound I-3 as a 6:4 mixture of two regioisomers as a red solid. Yield: 15 μmol (35%). 1H NMR (400MHz, MeOD): δ (ppm) 8.71 (s, 0.4H, Ar-CH, isom B), 8.32 (s, 0.6H, isom A), 8.00 (s, 0.6H, Ar-CH, isom A), 7.96 (d, J=9.0Hz, 0.4H, Ar-CH, isom B),7.85(d,J=9.0Hz,0.4H,Ar-CH,isom B),7.82(s,0.6H,Ar-CH,isom A),7.56(s,1H,Ar-CH),6.54(s,0.4H,Ar-CH,isom B),6.53(s,1H,0.6H,Ar-CH,isom A),5.21(s,0.8H,CH2-O,isom B),5.15(s,1.2H,CH2-O,isom A),4.44(s,3H,CH3-N),3.71–3.57(m,TEAB),3.57–3.51(m,2H,CH2-N),3.50–3.43(m,2H,CH2-N),2.85(t,J=6.2Hz,2H,Ar-CH2),2.69(s,1H,CH3 isom B),2.63(s,2H,CH3 isom A),2.56(s,1H,CH3 isom B),2.51(s,2H,CH3 isom A), 2.27 (t, J = 7.2, 2H, CH2-COO), 2.06–1.91 (m, 4H, CH2-CH2-N), 1.20 (t, J = 7.0Hz, TEAB). LC-MS(ESI): (positive ion) m / z 417 (M+H + ).

[0283]

[0284] Compound 8d (65mg, 0.132mmol) is dissolved in dry dichloromethane (1mL). Under N2 atmosphere, diisopropylethylamine (114μL, 0.66mmol) and methyl trifluoromethanesulfonate (300μL, 2.65mmol) are added. After 1 hour, volatiles are removed under reduced pressure. The crude product is then dissolved in methanol (10mL) and 0.5mL 4M NaOH aqueous solution is added. The reaction system is stirred at RT for 18 hours. Then, the solution is neutralized with acetic acid (0.15mL), and volatiles are removed under reduced pressure. The residue is first purified by flash column chromatography and then purified on a C18 column by RP chromatography to obtain compound I-4 as a red solid. Yield: 92μmol (69%). 1H NMR(400MHz,MeOD / CDCl3): δ(ppm)8.26(s,1H,Ar-CH),7.71(s,1H,Ar-CH),7.43(s,1H,,Ar-CH),7.42(s,1 H,Ar-CH),6.48(s,1H,Ar-CH),5.12(s,2H,CH2-O),4.44(s,3H,CH3-N),4.15(s,3H,CH3-O),4.03(s,3H,CH 3-O), 3.70–3.55 (m, 1H, TEAB), 3.50 (d, J = 5.6 Hz, 2H, CH2-N), 3.44 (d, J = 7.7 Hz, 2H, CH2-N), 2.82 (t, J = 6.2 Hz, 2H, Ar-CH2), 2.25 (t, J = 7.2 Hz, 2H, CH2-COO), 2.06–1.85 (m, 4H, CH2-CH2-N), 1.17 (t, J = 7.0 Hz, 1H, TEAB). LC-MS (ESI): (positive ion) m / z 449 (M+H + ).

[0285]

[0286] Compound 8e (80 mg, 0.159 mmol) was dissolved in dry 1,2-dichloroethane (2 mL) in a pressure tube. Under N2 atmosphere, methyl trifluoromethanesulfonate (360 μL, 3.18 mmol) and K2CO3 (109 mg, 0.795 mmol) were added, and the reaction system was heated to 110 ° C for 24 hours. The volatiles were removed under reduced pressure, and the red residue was purified by flash column chromatography. The intermediate was then dissolved in methanol (5 mL) and 0.35 mL of 4M NaOH aqueous solution was added. The reaction system was stirred at RT for 18 hours. Then, the solution was neutralized with 1N HCl (0.15 mL). The volatiles were removed under reduced pressure, and the crude product was first purified by flash column chromatography and then purified on a C18 column by RP chromatography to obtain compound I-5 as a red solid. Yield: 69 μmol (43%). 1H NMR (400MHz, MeOD / CDCl3): δ (ppm) 8.36 (s, 1H, Ar-CH), 8.16 (d, J = 9.5Hz, 1H, Ar-CH), 7.69–7.63(m,2H,Ar-CH),7.51(d,J=2.9Hz,1H,Ar-CH),6.54(s,1H,Ar-CH),5.19(d, J=13.7Hz,1H,O-CHH),5.12(d,J=13.7Hz,1H,O-CHH),4.47(s,3H,CH3-N),4.00(s,3H ,CH3-O),3.63(q,J=7.1Hz,1H,TEAB),3.58–3.47(m,1H,CHH-N),3.36–3.29(m,CHH-N under MeOH), 3.03–2.89 (m, 1H, Ar-CH), 2.27 (d, J = 7.1 Hz, 2H, CH2-COO), 2.04–1.84 (m, 4H, CH2-CH2-N), 1.47 (s, 3H, CH3), 1.46 (d, J = 6.5 Hz, 3H, CH3), 1.35 (s, 3H, CH3), 1.20 (t, J = 7.0 Hz, 2H, TEAB). LC-MS (ESI): (positive ion) m / z 461 (M+H + ).

[0287]

[0288] Compound 8f (310 mg, 0.182 mmol) was dissolved in dry 1,4-dioxolane (2 mL) in a pressure tube. Iodomethane (0.5 mL, 8 mmol) was added, and the reaction system was heated at 100 ° C in the dark. After 2 days, the volatiles were removed under reduced pressure, and the intermediate was then dissolved in methanol (5 mL), and 1 mL of 4M NaOH aqueous solution was added. The reaction system was stirred at RT for 18 hours. Then, the solution was neutralized with 1N HCl (0.15 mL). The volatiles were removed under reduced pressure, and the crude product was purified on a C18 column by preparative RP-HPLC to give compound I-6 as a red solid. Yield: 28 μmol (15%). 1H NMR (400MHz, MeOD): δ (ppm) 8.47 (s, 1H, Ar-CH), 8.15 (d, J = 9.0Hz, 1H, Ar-CH), 8.02 (dd, J = 9.0, 2.0Hz,1H,Ar-CH),7.98(d,J=2.0Hz,1H,Ar-CH),7.91(d,J=9.4Hz,1H,Ar-CH),6.80(dd,J=9.4, 2.6 Hz, 1H, Ar-CH), 6.51 (d, J = 2.7 Hz, 1H, Ar-CH), 5.25 (s, 2H, CH2-O), 4.49 (s, 3H, NCH3), 3.73 (s, 3H, OCH3), 3.59 (q, J = 7.1 Hz, 4H, CH2-N), 2.65 (q, J = 7.2 Hz, 6H, TEAB), 1.29 (t, J = 7.1 Hz, 6H, CH3 Et), 1.10 (t, J = 7.2 Hz, 9H, TEAB). LC-MS (ESI): (positive ion) m / z 377 (M+H + ).

[0289]

[0290] Compound 8g (65mg, 0.137mmol) is dissolved in dry dichloromethane (2mL). At 0°C under N2 atmosphere, methyl trifluoromethanesulfonate (77μL, 0.68mmol) and N, N-diisopropylethylamine (118μL, 0.68mmol) are added, then stirred for 4 hours at RT. Another portion of methyl trifluoromethanesulfonate (77μL, 0.68mmol) and N, N-diisopropylethylamine (118μL, 0.68mmol) and 2mL dry DCM are added. After another 2 hours, volatiles are removed under reduced pressure. The red residue is purified by flash column chromatography. The intermediate is then dissolved in methanol (10mL) and 0.375mL 4M NaOH aqueous solution is added. The reaction system is stirred for 2 hours at 60°C. Then, the solution is neutralized with acetic acid (0.09mL). The volatiles were removed under reduced pressure and the crude product was purified by RP chromatography on a C18 column to give compound 1-7 as a red solid. Yield: 9.8 μmol (7%). 1H NMR(400MHz,MeOD): δ(ppm)8.24(s,1H,Ar-CH),7.62(s,1H,Ar-CH),7.47(s,1H,Ar-CH),7 .34(s,1H,Ar-CH),6.48(s,1H,Ar-CH),6.29(s,2H,O-CH2-O),5.08(s,2H,CH2-O),4.38–4. 31 (m, 3H, CH3-N), 3.50 (t, J = 5.4 Hz, 2H, CH2-N), 3.44 (t, J = 7.8 Hz, 2H, CH2-N), 2.81 (m, 2H, Ar-CH2), 2.25 (m, 2H, CH2-COO), 2.02–1.87 (m, 4H, CH2-CH2-N), 1.20 (t, J = 7.0 Hz, 2H, TEAB). LC-MS (ESI): (positive ion) m / z 433 (M+H + ).

[0291]

[0292] Compound 8h (65mg, 0.117mmol) is dissolved in dry dichloromethane (2mL). At 0°C under N2 atmosphere, methyl trifluoromethanesulfonate (27μL, 0.234mmol) and N, N-diisopropylethylamine (41μL, 0.234mmol) are added, and then stirred for 2 hours at RT. Then methyl trifluoromethanesulfonate (54μL, 0.46mmol) and N, N-diisopropylethylamine (82μL, 0.46mmol) are added, and the reaction system is stirred for 2 hours at RT. Then, methyl trifluoromethanesulfonate (100μL, 0.88mmol) and N, N-diisopropylethylamine (82μL, 0.46mmol) are added, and the reaction system is stirred for 1 hour at RT, and then volatiles are removed under reduced pressure. The intermediate is dissolved in methanol (2mL) and 0.5mL 4M NaOH aqueous solution is added. The reaction system was stirred at RT overnight. Then, the solution was neutralized with acetic acid (0.24 mL). The volatiles were removed under reduced pressure and the crude product was purified by RP chromatography on a C18 column to give compound I-8 as a red solid. Yield: 70 μmol (60%). 1H NMR(400MHz,MeOD / CDCl3): δ(ppm)8.49(s,1H,Ar-CH),7.51(s,1H,Ar-CH),7.23(s,1H,Ar- CH),6.49(s,1H,Ar-CH),5.09(s,2H,CH2-O),4.40(s,3H,CH3-N),4.16(s,3H,CH3-O),4.15 (s, 3H, CH3-O), 3.98 (s, 3H, CH3-O), 3.54–3.50 (m, 2H, CH2-N), 3.47–3.41 (m, 2H, CH2-N), 2.84 (t, J=6.2 Hz, 2H, Ar-CH2), 2.24 (t, J=7.2 Hz, 2H, CH2-COO), 2.04–1.89 (m, 4H, CH2-CH2-N). LC-MS (ESI): (positive ion) m / z 479 (M+H + ).

[0293]

[0294] Compound 8i (50mg, 0.1mmol) is dissolved in dry dichloromethane (1mL). At 0°C under N2 atmosphere, N, N-diisopropylethylamine (208μL, 1.2mmol) and methyl trifluoromethanesulfonate (600μL, 5mmol) are added, and then stirred for 2 hours at RT. Methyl trifluoromethanesulfonate (600μL, 5mmol) and N, N-diisopropylethylamine (208μL, 1.2mmol) are then added, and the reaction system is stirred for 2 hours at RT. Then, volatiles are removed under reduced pressure. The red residue is purified by flash column chromatography. The intermediate is dissolved in methanol (5mL) and 0.25mL 4M NaOH aqueous solution is added. The reaction system is stirred overnight at RT. Then, the solution is neutralized with acetic acid (0.06mL). Volatiles are removed under reduced pressure, and the crude product is purified on a C18 column by RP chromatography to obtain compound I-9 as a red solid. Yield: 4.1 μmol (4%), red solid. 1H NMR(400MHz,MeOD / CDCl3): δ(ppm)8.30(s,1H,Ar-CH),8.13(s,1H,Ar-CH),7.54(s,1H,A r-CH),7.28(s,1H,Ar-CH),6.54(s,1H,Ar-CH),5.17–5.14(m,2H,CH2-O),4.80(t,J=8.4H z, 2H, CH2-CH2-O), 4.49–4.40 (m, 3H, CH3-N), 3.70–3.44 (m, 6H, CH2-N, CH2-CH2-O), 2.85 (t, J=6.2 Hz, 2H, Ar-CH2), 2.27 (t, J=7.2 Hz, 2H, CH2-COO), 2.04–1.93 (m, 4H, CH2-CH2-N). LC-MS (ESI): (positive ion) m / z 431 (M+H + ).

[0295] Example 2. General Synthesis of Chromenoquinoline Dye-Labeled Nucleotides

[0296] The chromophore quinoline dye of formula (I) (0.020 mmol) was co-evaporated with 2×2 mL of anhydrous N,N'-dimethylformamide (DMF) and then dissolved in 2 mL of anhydrous N,N'-dimethylacetamide (DMA). N,N-diisopropylethylamine (28.4 μL, 0.163 mmol) was added, followed by a 0.1 M solution of N,N,N',N'-tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate in anhydrous DMA (TSTU, 232 μL, 0.023 mmol). The reaction was stirred under nitrogen for 30 minutes at RT. At the same time, an aqueous solution of 2'-deoxyadenosine triphosphate-linker (0.01 mmol) was evaporated to dryness under reduced pressure and resuspended in 200 μL of a 0.1 M aqueous solution of triethylammonium bicarbonate (TEAB). The chromene and quinoline dye solution of activation is joined in the triphosphoric acid, and reaction system was stirred 18 hours under RT.At first on DEAE-Sephadex A25 (25g), pass through the ion exchange chromatography purification of crude product.Gather the fraction that contains triphosphate, and with the solvent evaporated under reduced pressure to dryness.Use YMC-Pack-Pro C18 post to further purify crude material through preparation type RP-HPLC.Final compound characterizes through LC-MS, analytical type RP-HPLC and UV-Vis spectroscopy.

[0297]

[0298] Compound ffA-LN3-I-1: Yield: 2.7 μmol (54%). LC-MS (ES): (negative ion) m / z 1346 (MH +),673(M-2H + ). UV-VISλ max =503nm. Fluorescence emission λ max =590nm.

[0299]

[0300] Compound ffA-LN3-I-2: Yield: 6.8 μmol (68%). LC-MS (ES): (negative ion) m / z 1330 (MH + ),665(M-2H + ). UV-VISλ max =500nm. Fluorescence emission λ max =582nm.

[0301]

[0302] Compound ffA-sPA-LN3-I-3: Yield: 6.3 μmol (63%). LC-MS (ES): (negative ion) m / z 1343 (MH + ),671(M-2H + ). UV-VISλ max =500nm. Fluorescence emission λ max =578nm.

[0303]

[0304] Compound ffA-sPA-LN3-I-4: Yield: 7.8 μmol (78%). LC-MS (ES): (negative ion) m / z 1375 (MH + ),687(M-2H + ). UV-VISλ max =500nm. Fluorescence emission λ max =578nm.

[0305]

[0306] Compound ffA-LN3-I-5: Yield: 7.3 μmol (73%). LC-MS (ES): (negative ion) m / z 1388 (MH + ),694(M-2H + ). UV-VISλ max =501nm. Fluorescence emission λ max =585nm.

[0307]

[0308] Compound ffA-LN3-I-6: Yield: 3.1 μmol (31%). LC-MS (ES): (negative ion) m / z 1304 (MH + ),652(M-2H + ). UV-VISλ max =495nm. Fluorescence emission λ max =574nm.

[0309]

[0310] Compound ffA-sPA-LN3-I-8: Yield: 6.9 μmol (69%). LC-MS (ES): (negative ion) m / z 1405 (MH + ),702(M-2H + ). UV-VISλ max =500nm. Fluorescence emission λ max =583nm.

[0311]

[0312] Compound ffA-AOM-AOL-I-4: Yield: 10 μmol (50%). LC-MS (ES): (negative ion) m / z 1405 (MH + ),702(M-2H + ). UV-VISλ max =500nm. Fluorescence emission λ max =578nm.

[0313]

[0314] Compound ffA-(DB)-AOM-AOL-I-4: Yield: 2.1 μmol (21%). LC-MS (ES): (negative ion) m / z 1407 (MH + ),703(M-2H + ). UV-VISλ max =500nm. Fluorescence emission λ max =578nm.

[0315] Example 3. Spectral properties of ffA nucleotides conjugated with chromenoquinoline dyes

[0316] In this example, the spectroscopic properties of several fully functionalized A nucleotides (ffA) conjugated to the chromenoquinoline dyes described herein are characterized. Figure 1Shown are the fluorescence absorption spectra of ffA nucleotides conjugated to chromenoquinoline dyes 1-1 to 1-6 and 1-8 as 2 μM solutions in Universal Scan Mix (USM, 1 M Tris pH 7.5, 0.05% Tween, 20 mM sodium ascorbate, 10 mM ethyl gallate). FIG. 2A to FIG. 2D Shown is the fluorescence emission spectrum of the WA nucleotides conjugated with chromene and quinoline dyes I-1 to I-6 and I-8 obtained in USM using 450nm or 520nm as the excitation wavelength. Use quartz or plastic cuvettes to obtain spectrum on Agilent Cary 100UV-Vis spectrophotometer and on Cary Eclipse fluorescence spectrophotometer. Observe that the chromene and quinoline dyes described herein can be excited under blue and green light sources and also have strong fluorescence emission.

[0317] Example 4. Stability of ffA labeled with chromenoquinoline dye

[0318] The stability of compounds ffA-sPA-I-3 and ffA-sPA-I-4 in high pH aqueous solutions was evaluated by incubating 10 μM solutions of a given compound in two buffers: 1) 50 mM ethanolamine buffer, pH 9.6, 50 mM NaCl, 1 mM EDTA, 0.02% CHAPS, 4 mM MgSO4; 2) 50 mM glycine buffer, pH 9.8, 50 mM NaCl, 1 mM EDTA, 0.2% CHAPS, 4 mM MgSO4, at 45°C in the dark for 6 days. At set time points, the UV-VIS absorption and fluorescence emission of the solution were measured using a quartz cuvette on an Agilent Cary 100 UV-Vis spectrophotometer and on a Cary Eclipse fluorescence spectrophotometer. In addition, an aliquot of the solution was taken and analyzed by analytical HPLC. Figure 3A and Figure 3B The fluorescence emission of ffA-sPA-I-3 and ffA-sPA-I-4 is shown to decrease very slowly over time, indicating that the chromenoquinoline dyes I-3 and I-4 are stable under these conditions compared to ffC labeled with leucomarin reference dye A under the same conditions. Coumarin reference dye A is disclosed in U.S. Patent Publication No. 2018 / 0094140 and has a structural moiety when conjugated to ffC.

[0319] In addition, the stability of compounds ffA-sPA-I-3 and ffA-sPA-I-4 in buffers suitable for nucleotide storage was evaluated by incubating 10 μM solutions in two buffers: 1) 10 mM Tris buffer, pH 8.0; 2) 100 mM MOPS buffer, pH 7.0, at 40°C in the dark for 14 days. At set time points, the UV-VIS absorption and fluorescence emission of the solution were measured using a quartz cuvette on an Agilent Cary 100 UV-Vis spectrophotometer and on a Cary Eclipse fluorescence spectrophotometer. In addition, an aliquot of the solution was taken and analyzed by analytical HPLC. Figure 3C and Figure 3D It is shown that ffA-sPA-I-3 and ffA-sPA-I-4 retained >90% of the fluorescence after 14 days in Tris pH 8.0 and >75% of the fluorescence after 14 days in MOPS pH 7.0 compared to coumarin reference dye A under the same conditions.

[0320] Example 5. Illumina iSeq TM 100 sequencing experiments on instruments

[0321] In Illumina iSeq TM 100 instruments were tested with fluoroquinoline dyes labeled as herein described FA, which had been set to take the first image in the case of green excitation light (about 520nm) and take the second image in the case of blue excitation light (about 450nm). Modify the sequencing recipe to perform standard SBS cycles (incorporation, imaging afterwards, and cracking afterwards), reaching 1 × 300 cycles. The incorporation mixture used in each of these experiments contained the following four ffNs in 50mM ethanolamine buffer, pH 9.6, 50mM NaCl, 1mM EDTA, 0.2% CHAPS, 4mM MgSO4 and DNA polymerase: ffA labeled with fluoroquinoline dyes of formula (I), ffC (e.g. ffC-linker-coumarin reference dye A) that can be excited with the blue light of 450nm, ffT (e.g. ffT-linker-NR550s0) and unlabeled ffG (dark ffG) that can be excited with green light. FIG. 4A to FIG. 4E Shown is a scatter plot of the resulting incorporation mixture having ffA nucleotides labeled at cycle 26 with chromenoquinoline dyes 1-1, 1-2, 1-3, 1-4 and 1-5, respectively. Figure 4F Phasing and prephasing metrics over 1 x 300 cycles are shown. All ffAs tested showed excellent quality scatter plots and sequencing metrics.

[0322] Table 1 shows the TMPhasing, prephasing, PhiX error rate and %Q30 metrics for 2×300 cycles run on a 100 instrument were performed using a spike-in mixture containing ffA-sPA-LN3-I-4. The instrument was set to take the first image with green excitation light and the second image with blue excitation light, and the recipe was modified to perform standard SBS cycles (spiking, then imaging, then cutting) for 2×300 cycles. The spike-in mixture used in these experiments contained nucleotides ffA-sPA-LN3-I-4, ffC (e.g., ffC-linker-coumarin reference dye A) that can be excited with 450nm blue light, ffT (e.g., ffT-linker-NR550s0) that can be excited with green light, and dark ffG in 50mM ethanolamine buffer, pH 9.6, 50mM NaCl, 1mM EDTA, 0.2% CHAPS, 4mM MgSO4 and DNA polymerase.

[0323] Table 1. iSeq using ffA-sPA-LN3-I-4 TM 100 sequencing metrics (2×300 cycles)

[0324]

[0325] Table 2 shows the TM The phasing, pre-phasing, PhiX error rate and %Q30 metrics of 2×150 cycles and 2×300 cycles run on the 100 instrument were performed using a spike-in mixture containing ffA-AOM-AOL-I-4. The instrument was set to take the first image in the case of green excitation light and take the second image in the case of blue excitation light, and the recipe was modified to perform standard SBS cycles (spiking, then imaging, then cutting) for 2×300 cycles. The spike-in mixture used in these experiments contained nucleotides ffA-AOM-AOL-I-4, ffC that can be excited with 450nm blue light and can be cleaved with palladium complex, ffT that can be excited with 520nm green light and can be cleaved with palladium complex, and dark ffG that can be cleaved with palladium complex. The lysis solution used in these experiments contained 100 mM diethylethanolamine buffer pH 9.5, 100 mM tris(hydroxypropyl)phosphine, 10 mM [allylpalladium chloride (AllylPdCl)]2, 10 mM sodium ascorbate, 1 M NaCl, 0.1% Tween20.

[0326] Table 2. iSeq using ffA-AOM-AOL-I-4 TM 100 sequencing metrics (2×150 cycles and 2×300 cycles)

[0327]

Claims

1. A compound of formula (I), a salt or meso form thereof: Where R 1 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12a and R 12b each of which is independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, (C1-C6 alkoxy)C1-C6 alkyl, optionally substituted amino, amino(C1-C6 alkyl), halo, cyano, hydroxy, hydroxy(C1-C6 alkyl), nitro, sulfonyl, sulfo, sulfinyl, sulfonate, S-sulfonamido, or N-sulfonamido; R 2 is carboxyl or –C(O)NR 16 R 17 Substituted C1-C6 alkyl, and each R 16 and R 17 are independently carboxy, carboxylate, –C(O)OR 15 , sulfonyl or sulfonate substituted C1-C6 alkyl R 3 is H, C1-C6 alkyl or substituted C1-C6 alkyl; and R 6 is C1-C6 alkyl or substituted C1-C6 alkyl; Alternatively, R 3 and R 4 together with the atoms to which they are attached form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 5- to 10-membered heterocyclyl; Alternatively, R 8 and R 9 Together with the atoms to which they are attached, they form an optionally substituted C6-C 10 aryl, optionally substituted 3- to 10-membered carbocyclyl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 3- to 10-membered heterocyclyl.

2. The compound according to claim 1, wherein R 3 It is a C1-C6 alkyl group.

3. The compound according to claim 1, wherein the compound of formula (I) is also represented by formula (Ia), its salt or meso form: Where R 13a , R 13b , R 14a and R 14b each of which is independently H, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, (C1-C6 alkoxy)C1-C6 alkyl, optionally substituted amino, amino(C1-C6 alkyl), halo, cyano, hydroxy, hydroxy(C1-C6 alkyl), nitro, sulfonyl, sulfo, sulfinyl, sulfonate, S-sulfonamido, or N-sulfonamido; and By solid and dotted lines The bond represented by is selected from the group consisting of single bonds and double bonds, provided that when When it is a double bond, R 14b Does not exist.

4. The compound according to claim 3, wherein the solid line and the dotted line The bond indicated is a double bond.

5. The compound according to claim 4, wherein R 14a It is H or C1-C6 alkyl.

6. The compound according to claim 5, wherein R 14a It's methyl.

7. The compound according to claim 3, wherein the solid line and the dotted line The bond represented is a single bond.

8. The compound according to claim 7, wherein R 14a is H, and R 14b It is a C1-C6 alkyl group.

9. The compound according to claim 7, wherein R 14a and R 14b Each of is H.

10. A compound according to any one of claims 3 to 9, wherein R 13a and R 13b Each of is H.

11. A compound according to any one of claims 3 to 9, wherein R 13a and R 13b Each of is a C1-C6 alkyl group.

12. The compound according to claim 11, wherein R 13a and R 13b Each of is methyl.

13. A compound according to any one of claims 1 to 4, wherein R 1 It's H.

14. A compound according to any one of claims 1 to 4, wherein each R 5 and R 11 It's H.

15. A compound according to any one of claims 1 to 4, wherein R 6 It is a C1-C6 alkyl group.

16. A compound according to any one of claims 1 to 4, wherein R 6 is carboxyl or –C(O)NR 16 R 17 substituted C1-C6 alkyl, and wherein each R 16 and R 17 are independently carboxy, carboxylate, –C(O)OR 15 , sulfonyl or sulfonate substituted C1-C6 alkyl.

17. A compound according to any one of claims 1 to 4, wherein R 7 , R 8 , R 9 and R 10 At least one of them is independently C1-C6 alkyl or C1-C6 alkoxy.

18. A compound according to any one of claims 1 to 4, wherein R 7 , R 8 , R 9 and R 10 At least one of the above is carboxyl, carboxylate, sulfonate, sulfonate, -C(O)OR 15 or –C(O)NR 16 R 17 substituted C1-C6 alkyl, and wherein each R 16 and R 17 are independently H or substituted by carboxyl, carboxylate, –C(O)OR 15 , sulfonyl or sulfonate substituted C1-C6 alkyl.

19. A compound according to any one of claims 1 to 4, wherein R 8 and R 9 Together with the atoms to which they are attached they form an optionally substituted 5- or 6-membered heterocyclyl.

20. The compound according to claim 19, wherein the optionally substituted 5- or 6-membered heterocyclic radical is 21. A compound according to any one of claims 1 to 4, wherein R 12a and R 12b Each of is H.

22. The compound according to claim 1, selected from the group consisting of: or their salts or meso forms.

23. A nucleotide or oligonucleotide labelled with a compound according to any one of claims 1 to 22.

24. A nucleotide or oligonucleotide according to claim 23, wherein the compound is via R of formula (I) 2 or R 6 A carboxyl group is attached to the nucleotide or oligonucleotide.

25. The nucleotide or oligonucleotide according to claim 23, wherein the compound is via R of formula (I) 7 , R 8 , R 9 and R 10 A carboxyl group of one of the nucleotides or oligonucleotides is attached to the nucleotide or oligonucleotide.

26. The nucleotide or oligonucleotide according to any one of claims 23 to 25, wherein the compound is attached to the C5 position of a pyrimidine base or the C7 position of a 7-deazapurine base of the nucleotide or oligonucleotide via a linker moiety.

27. The nucleotide or oligonucleotide according to any one of claims 23 to 25, further comprising a 3'OH capping group covalently attached to the ribose or deoxyribose of the nucleotide.

28. The nucleotide or oligonucleotide according to any one of claims 23 to 25, wherein the nucleotide or oligonucleotide is an oligonucleotide that hybridizes to at least a portion of a target polynucleotide.

29. The oligonucleotide of claim 28, wherein the target polynucleotide is immobilized on a solid support.

30. The oligonucleotide of claim 29, wherein the solid support comprises an array of a plurality of immobilized target polynucleotides.

31. A kit comprising a first nucleotide labelled with a first compound according to any one of claims 23 to 30.

32. The kit of claim 31, further comprising a second nucleotide, wherein the second nucleotide is labeled with a second compound that is different from the first compound of the first labeled nucleotide.

33. The kit of claim 32, wherein the first labeled nucleotide and the second labeled nucleotide are capable of being excited using a first light source wavelength.

34. A kit according to claim 32 or 33, further comprising a third nucleotide, wherein the third nucleotide is labeled with a third compound different from the first compound and the second compound, and wherein the first labeled nucleotide and the third labeled nucleotide can be excited using a second light source wavelength.

35. The kit of claim 34, further comprising a fourth nucleotide, and wherein the fourth nucleotide is unlabeled or dark.

36. The kit of claim 34, wherein each of the first labeled nucleotide, the second labeled nucleotide, and the third labeled nucleotide has an emission spectrum that can be detected in a single detection channel.

37. The kit according to any one of claims 31 to 33, further comprising a DNA polymerase and one or more buffer compositions.

38. A method for determining the sequence of a target polynucleotide, the method comprising: (a) contacting a primer polynucleotide / target polynucleotide complex with one or more labeled nucleotides, wherein at least one of the labeled nucleotides is a nucleotide according to any one of claims 23 to 27, and wherein the primer polynucleotide is complementary to at least a portion of the target polynucleotide; (b) incorporating a labeled nucleotide into the primer polynucleotide to generate an extended primer polynucleotide; as well as (c) performing one or more fluorescence measurements on the extended primer polynucleotide to determine the identity of the incorporated nucleotide.

39. The method of claim 38, wherein the primer polynucleotide / target polynucleotide complex is formed by contacting the target polynucleotide and a primer polynucleotide that is complementary to at least a portion of the target polynucleotide.

40. The method of claim 38 or 39, further comprising (d) removing the label and 3'OH blocking group from the nucleotide incorporated into the primer polynucleotide.

41. The method of claim 40, further comprising (e) washing the removed label and 3'OH blocking group from the primer polynucleotide.

42. The method of claim 41, further comprising repeating steps (a) to (e) until the sequence of at least a portion of the target polynucleotide chain is determined.

43. The method of claim 42, wherein steps (a) to (e) are repeated at least 50 times.

44. The method of claim 38 or 39, wherein the nucleotide or oligonucleotide is a nucleotide or oligonucleotide comprising a 3'OH capping group covalently attached to the ribose or deoxyribose of the nucleotide, wherein the label and the 3'OH capping group are removed in a single chemical reaction.

45. The method of claim 38 or 39, wherein the method is performed on an automated sequencing instrument, and wherein the automated sequencing instrument comprises two light sources operating at different wavelengths.